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MYCN ampliﬁcation and ATRX mutations are
incompatible in neuroblastoma
Maged Zeineldin1,18, Sara Federico2,18, Xiang Chen 3,4,18, Yiping Fan3, Beisi Xu 3, Elizabeth Stewart2,
Xin Zhou3, Jongrye Jeon1, Lyra Grifﬁths1, Rosa Nguyen1, Jackie Norrie1, John Easton3, Heather Mulder 3,
Donald Yergeau3, Yanling Liu3, Jianrong Wu5, Collin Van Ryn6, Arlene Naranjo6, Michael D. Hogarty7,
Marcin M. Kamiński 8, Marc Valentine9, Shondra M. Pruett-Miller 10, Alberto Pappo2, Jinghui Zhang 3,
Michael R. Clay 11, Armita Bahrami11, Peter Vogel 11, Seungjae Lee11, Anang Shelat 12, Jay F. Sarthy13,
Michael P. Meers13, Rani E. George14, Elaine R. Mardis 15, Richard K. Wilson15, Steven Henikoff13,16,
James R. Downing11 & Michael A. Dyer1,4,16,17*

Aggressive cancers often have activating mutations in growth-controlling oncogenes and
inactivating mutations in tumor-suppressor genes. In neuroblastoma, ampliﬁcation of the
MYCN oncogene and inactivation of the ATRX tumor-suppressor gene correlate with high-risk
disease and poor prognosis. Here we show that ATRX mutations and MYCN ampliﬁcation are
mutually exclusive across all ages and stages in neuroblastoma. Using human cell lines and
mouse models, we found that elevated MYCN expression and ATRX mutations are incompatible. Elevated MYCN levels promote metabolic reprogramming, mitochondrial dysfunction, reactive-oxygen species generation, and DNA-replicative stress. The combination of
replicative stress caused by defects in the ATRX–histone chaperone complex, and that
induced by MYCN-mediated metabolic reprogramming, leads to synthetic lethality. Therefore, ATRX and MYCN represent an unusual example, where inactivation of a tumorsuppressor gene and activation of an oncogene are incompatible. This synthetic lethality may
eventually be exploited to improve outcomes for patients with high-risk neuroblastoma.
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euroblastoma is the most common extracranial solid
tumor of childhood1. MYCN ampliﬁcation and age at
diagnosis are the two most powerful predictors of outcome, with survival rates 5–10 times higher in infants than in
adolescents or young adults1,2. Previous genomic analyses of stage
4 pediatric neuroblastoma samples identiﬁed the ATRX mutations in patients that were typically older than 5 y, had an
indolent disease course, and poor overall survival (OS)1,3.
One important function of ATRX is recognition of guanine
(G)-rich stretches of DNA and deposition of the H3.3 histone
variant to prevent the formation of G-quadruplex (G4) structures,
which can block DNA replication or transcription4,5. G-rich
repeats are also found at telomeres and centromeres; ATRX forms
a complex with DAXX to deposit H3.3 in those regions to
maintain their integrity4,5. In cells lacking ATRX, H3.3 is not
efﬁciently deposited at the telomeric G-rich regions, G4 structures
form, and replication forks stall4,5. Consequently, telomeres
undergo homologous recombination leading to alternative
lengthening of telomeres (ALT)6.
The formation of G4 structures in other G-rich repetitive
regions of the genome can cause replicative stress7,8 or block
transcription9. Indeed, H3.3 is deposited at actively transcribed
genes in addition to telomeres and pericentromeric DNA9. ATRX
may also affect transcription by targeting the PRC2 complex to
particular regions of the genome10. Consequently, in ATRXdeﬁcient cells, PRC2-mediated modiﬁcation of H3 to H3K27me3
lacks speciﬁcity, and genes that are normally repressed by polycomb are deregulated10.
MYCN regulates diverse cellular processes during development
and in cancer. For example, elevated MYCN leads to increased
glycolytic ﬂux and glutaminolysis to promote metabolic reprogramming associated with tumorigenesis in a variety of cancers
including neuroblastomas11,12. MYCN-induced glutaminolysis in
neuroblastoma elevates reactive-oxygen species (ROS) and DNAreplicative stress13,14. Indeed, one of the hallmarks of neuroblastoma is the DNA mutation signature associated with ROS
induced DNA damage. Consequently, neuroblastoma cells exhibit
increased sensitivity to pharmacological agents that induce oxidative stress13,14. Here we demonstrate that the DNA-replicative
stress induced by ATRX mutations and MYCN ampliﬁcation
cause synthetic lethality in neuroblastoma. This is unusual
because oncogene activation and tumor-suppressor inactivation
often work in concert to promote tumorigenesis not cancer
cell death.
Results
ATRX and MYCN mutations in neuroblastoma. To complement previous neuroblastoma studies from the Therapeutically
Applicable Research to Generate Effective Treatment (TARGET)
initiative15 and the Pediatric Cancer Genome Project (PCGP)3,16,
we obtained neuroblastoma samples from 473 patients (122
unpaired and 351 paired tumor/germline) from the Children’s
Oncology Group (COG) (Table 1). We identiﬁed singlenucleotide variations, small indels, and other somatic mutations
in the coding region of ATRX via custom capture and Illumina
sequencing using probes spanning the entire ATRX locus and
whole-exome sequencing of 828 germline and tumor samples. We
also included MYCN in the capture probe set to determine its
copy number. We identiﬁed 19 somatic ATRX mutations, 15 of
those are internal deletions predicted to encode truncated proteins (Fig. 1a).
Signiﬁcantly higher ATRX-mutation frequencies are detected
in patients with International Neuroblastoma Staging System
(INSS) stage 4 disease (8.6%), high-risk subgroup (14.6%), 11q
loss of heterozygosity (LOH), or unfavorable histology and in
2

Table 1 Distribution of ATRX mutations in neuroblastoma.
Classiﬁcationa

Grouping

N(%)b

INSS stage

Non-stage 4
Stage 4
Low/intermediate
High
Female
Male
Not ampliﬁed
Ampliﬁed
Not ampliﬁed
Ampliﬁed
No mutation
Mutation
Hyperdiploid
Diploid
No
Yes
No
Yes
Favorable
Unfavorable
<18 months
≥18 months
<18 months
18 mo-5 yrs
5–12 yrs
>12 years
Differentiating
Poorly/
undifferentiated
Low/intermediate
High
Black
other

312
162
375
96
253
221
431
39
447
28
454
21
277
179
301
27
290
38
314
136
213
261
213
76
152
33
43
283
298
32
55
378

Risk Group
Sex
MYCN (FISH)
MYCN (NGS)
ALK
Ploidy
11q LOH
1p LOH
Histology
Age at
diagnosis
Age at
diagnosis
Grade
MKI
Race

p-value

(65.8)
(34.2)
(79.6)
(20.4)
(53.4)
(46.6)
(91.7)
(8.3)
(94.1)
(5.9)
(95.6)
(4.4)
(60.7)
(39.3)
(91.8)
(8.2)
(88.4)
(11.6)
(69.8)
(30.2)
(44.9)
(55.1)
(44.9)
(16.0)
(32.1)
(7.0)
(13.2)
(86.8)

ATRX mutation
(%)c
5 (1.6)
14 (8.6)
5 (1.3)
14 (14.6)
12 (4.7)
7 (3.2)
18 (4.2)
1 (2.6)
19 (4.3)
0 (0)
17 (3.7)
2 (9.5)
10 (3.6)
8 (4.5)
5 (1.7)
5 (18.5)
9 (3.1)
1 (2.6)
1 (0.3)
17 (12.5)
0 (0)
19 (7.3)
0 (0)
1 (1.3)
15 (9.9)
3 (9.1)
3 (7.0)
15 (5.3)

(90.3)
(9.7)
(12.7)
(87.3)

18
0
5
12

0.2356

(6.0)
(0)
(9.1)
(3.2)

0.0002
4.4e-7
0.3830
1.0000
0.6180
0.2026
0.6454
4.9e-4
1.0000
9.3e-9
0.00001
9.0e-6

0.7168

0.0348

aINSS international neuroblastoma staging system, MYCN ampliﬁcation was assessed by FISH at
each COG participating center and by next-generation sequencing (NGS) in our sequence
analysis, MKI mitosis–karyorrhexis index.
bN number of patients with percentage in parentheses.
cThere were 19 ATRX mutations identiﬁed but for some tumors, the classiﬁer was not applied so
the total number of samples and the total number of ATRX-mutant samples is lower.

those who are 18 mo or older at diagnosis (Table 1, Fig. 1b).
ATRX-mutant neuroblastomas were signiﬁcantly more likely to
have ALT than ATRX wild-type tumors (89.5% (17/19) vs.
22.2% (4/18); p < 0.0001, two-tailed Fisher’s exact test). In
addition, black patients had a signiﬁcantly higher frequency of
ATRX mutation than did those in other racial categories (9.1%
vs. 3.3%; p = 0.0348, two-tailed Fisher’s exact test) (Table 1).
ATRX mutation frequency did not differ based on sex, ALK
status, tumor grade, mitosis–karyorrhexis index, or ploidy
(Table 1).
ATRX mutations were associated with signiﬁcantly lower 4-year
event-free survival (EFS) rates among the groups with non–INSS
stage 4 disease (p = 0.0007, two-tailed Fisher’s exact test), INSS
stage 4 disease (p = 0.0128, two-tailed Fisher’s exact test), ages 5–12
y (p = 0.0006, two-tailed Fisher’s exact test) and older than 12 y
(p = 0.0038, two-tailed Fisher’s exact test) at diagnosis in the COG
cohort (Supplementary Data 1 and Fig. 1c, d). Compared with those
without a mutation, patients harboring an ATRX mutation were 5.0
times more likely to experience an adverse event (p < 0.0001) and
3.4 times more likely to die of their disease (p = 0.0046, two-tailed
Fisher’s exact test) (Supplementary Data 1).
In the cohort of 819 tumors, ATRX mutations (n = 64) and
MYCN ampliﬁcation (n = 140) showed statistically signiﬁcant
mutual exclusivity (p = 0.0037, Cochrane-Mantel-Haenszel test)
(Fig. 1e and Supplementary Note 1). Only 1 of 819 (0.1%) tumors
had both lesions. However, this was an unusual discordant
sample because it was scored as MYCN-ampliﬁed by ﬂuorescence
in situ hybridization (FISH) in COG’s neuroblastoma reference
lab but non-ampliﬁed based on normalized read depth from our
custom capture Illumina next-generation sequencing data
(Supplementary Fig. 1A). To resolve this discrepancy, we repeated
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the FISH analysis and found regional heterogeneity of MYCN
ampliﬁcation (Fig. 1f–h). Speciﬁcally, the region with MYCN
ampliﬁcation had a high mitosis–karyorrhexis index and was less
likely to have ultrabright telomere foci, characteristic of ALT, in

ATRX-mutant neuroblastoma cells (Fig. 1f–h and Supplementary
Fig. 1B–E).
To determine whether ATRX mutations and MYCN ampliﬁcation are incompatible in vivo, we conditionally inactivated ATRX
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Fig. 1 ATRX mutations are mutually exclusive of MYCN ampliﬁcation in neuroblastoma. a Summary of ATRX mutations in the COG and PCGP cohorts.
Black bars indicate the deleted amino acids; red indicates nonsense mutations; orange indicates frameshift mutations; and blue indicates missense mutations.
The major protein domains are shaded in blue. b Bar plot of the percentage of the 819 patients analyzed in this study with ATRX mutations for each age and
stage. c, d EFS for patients with neuroblastoma with or without ATRX mutations for stages 1–3 or stage 4 for all age groups. P values were calculated using Cox
model. e Heatmap of the distribution of mutations in MYCN, ATRX, and ALK in the COG cohort. Only those tumors with a mutation in at least one of the three
genes are indicated. f Micrograph of MYCN FISH (red) for the one neuroblastoma sample with an ATRX mutation and MYCN ampliﬁcation showing regional
ampliﬁcation (dashed line). The PAX3 (2q35) probe (green) is the control. g Micrograph of a neuroblastoma cell with MYCN homogenously staining region
within a region of the tumor that has MYCN ampliﬁcation (box within the dashed line region in f. h Micrograph of a neuroblastoma cell with two copies of MYCN
outside of the region with ampliﬁcation (box outside of the dashed line region). i Representative photograph of neuroblastoma tumors from a LSL-MYCN;DbhiCre mouse. All the tumors developed in this mouse cohorts were harvested and examined. j Micrographs of the histology of the tumor shown in i. The boxed
region in each micrograph is magniﬁed in the lower left panel of each image. Three tumors from each group of mice were examined by both H&E and immunestaining. k, l Survival curves for two mouse models of neuroblastoma with or without conditional ATRX deletion. The numbers of mice in each group are
indicated. P values were calculated using Log-rank test. Scale bar: f, 5 μm, g, h, 1 μm. COG Children’s Oncology Group, PCGP Pediatric Cancer Genome Project,
INSS International Neuroblastoma Staging System, H&E hematoxylin and eosin, TH tyrosine hydroxylase.

in two genetically engineered neuroblastoma mouse models
(Fig. 1i–l)8,17,18. One model (LSL-MYCN;Dbh-iCre) is a transgenic
line with conditional expression of MYCN from Rosa26a locus by
Cre expressed in the dopaminergic cells of the sympathoadrenal
lineage19. The other model includes the Th-ALKF1174L transgene
that potentiates MYCN-mediated tumorigenesis20. For each of these
models, tumor formation was reduced, and survival was signiﬁcantly increased when Atrx was simultaneously inactivated with
elevated MYCN expression (Fig. 1k–l). The few tumors that did
form in the AtrxLox/Lox;LSL-MYCN;Dbh-iCre;ALKF1174L mice all
had evidence of an intact Atrx allele, suggesting that rare cells that
did not undergo Atrx inactivation contributed to tumor formation.
It is also possible that ALK signaling partially rescued the synthetic
lethality. Atrx inactivation has been shown to reduce cell survival in
brain, muscles and testes8,21,22. Histopathological review of adrenal
gland and paravertebral sympathetic ganglia from LSL-MYCN;DbhiCre and AtrxLox/Lox;LSL-MYCN;Dbh-iCre mice at 3 weeks and 1
year of age showed no differences (Supplementary Fig. 2,
Supplementary Note 2), suggesting that the lack of tumor formation
was not due to death of the NB cell of origin.
ATRX mutations are incompatible with elevated MYCN. To
extend our data to humans, we characterized the expression of
MYCN, ATRX, and DAXX proteins across 12 human cancer cell
lines (Fig. 2a). We used eight neuroblastoma cell lines, including
three MYCN-ampliﬁed lines (IMR32, SKNBE2, NB-5) or moderately elevated levels of MYCN (NBL-S) (Supplementary
Data 2), two lines (SKNMM and CHLA90) produce ATRX with
an in-frame deletion (ATRXIFD) and are diploid for MYCN
(Fig. 2a), one osteosarcoma cell line with no detectable expression
of ATRX (U2OS) and three lines as controls.
To knockdown ATRX, we used two different lentiviral vectors
expressing shRNAs targeting ATRX (#9 and #20) (Fig. 2b). The
optimal knockdown was ~ 86% in HeLa cells after 48 h with ATRX
shRNA–20. Two weeks after introducing shRNAs, telomere
content, ALT status and the proportions of cells in different phases
of the cell cycle did not differ in any cell line tested (Supplementary
Fig. 3A–I). Knocking down ATRX decreased colony formation in
MYCN-ampliﬁed neuroblastoma cells (IMR32 and NB-5) but not
cell lines expressing wild-type MYCN (Fig. 2c, d).
To inactivate ATRX in the MYCN-ampliﬁed neuroblastoma
cell lines, we designed and validated two guide RNAs (gRNA-2
and gRNA-5) to exon 6 of ATRX (Fig. 2e, f). We transfected
293T, SKNBE2, and IMR32 cells with each gRNA and a plasmid
expressing Cas-9 and puriﬁed the transfected cells by ﬂow
cytometry. At 2, 10, and 14 days after plating the puriﬁed cells, we
harvested DNA, performed PCR using primers spanning both of
the two gRNA-target sequences, and performed Illumina MiSeq
analysis to calculate the proportion of mutated alleles in each
4

sample. Although the ATRX-mutant alleles were abundant in
293T and SKNBE2 cells 2 days after plating, those cells harboring
ATRX-mutant alleles were lost by 10 days in culture (Fig. 2g and
Supplementary Fig. 3J). In MYCN-ampliﬁed IMR32 cells, no
mutant alleles were detected at any timepoint, though a control
gRNA to the AAVS1 locus led to efﬁcient mutagenesis. A similar
study performed with a gRNA to DAXX had no effect on the
viability of 293T, SKNBE2, or IMR32 cells (Supplementary
Fig. 3K-M). Taken together, our data suggest that ATRX
inactivation is incompatible with MYCN ampliﬁcation in
neuroblastoma, which is consistent with data from the Project
Achilles (https://depmap.org/portal/achilles/).
Next, we induced the expression of MYCN in ATRX-mutant
neuroblastoma cells by using a doxycycline-inducible vector
(Fig. 2h). Initially, we used two ATRX-mutant cell lines (SKNMM
and U2OS), a MYCN-ampliﬁed cell line (SKNBE2), and a cell line
that is wild-type for both genes (SKNFI) (Fig. 2a). The levels of
MYCN achieved with doxycycline induction in both ATRXmutant lines were similar to those in MYCN-ampliﬁed cell lines
(Fig. 2h).
The growth rates of SKNFIMYCN and SKNBE2MYCN cells, after
10 days in culture ± doxycycline, showed no difference with
induction of MYCN expression, but by 6 days in culture, the two
ATRX-mutant lines showed a marked loss of cells (Fig. 2i, j). A
parallel experiment performed with stable cell lines that had only
the doxycycline-inducible vector lacking MYCN showed no effect
on cell growth. More than 95% of the cells in the SKNMMMYCN
cultures were lost by 8–10 days in the presence of doxycycline
(Fig. 2k). Live imaging of cells ± doxycycline on Days 6–8, the
peak period of cell loss (Fig. 2l), enabled us to determine the
timing of cell death in 44 cells from 13 different movies
(Supplementary Data 3). In total, 54% of the cells died after
initiating cytokinesis; the remaining cells died 20.2 ± 12.8 h
(mean ± standard deviation) after cytokinesis. These data were
extended to ﬁve other ATRX-mutant cell lines including two
glioma cell lines that had isogenic ATRX-wild-type controls
(Supplementary Fig. 4)23. A marker of DNA-replicative stress
(pRPA32) was upregulated in the absence of ATRX and in the
presence of doxycycline. There was no effect of ectopic MYCN
expression on a DAXX-mutant cell line (Supplementary Fig. 4A,
B). A small number of SKNMMMYCN cells escaped cell death and
continued to grow for 45 days in the presence of doxycycline. The
ATRXIFD was still expressed and the MYCN transgene was still
present, but MYCN protein was lost (Fig. 2m).
To determine whether an elevated level of MYCN is incompatible with ATRX mutation in human neuroblastoma cells in vivo,
we performed an in vivo growth competition assay. In one cohort of
mice, SKNMMMYCN cells labeled with luciferase and YFP were
mixed in a 1:1 ratio with unlabeled control SKNMMCONT cells,
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week, and ultrasound was performed every 2 weeks. Animals were
randomized to +doxycycline and –doxycycline groups once the
tumor was larger than 14 mm3 by three-dimensional ultrasound
and/or 1.4 × 107 photons/s/cm2/sr by xenogen imaging (Supplementary Data 4). The SKNMMMYCN cells were outcompeted by the
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Fig. 2 ATRX mutations and MYCN ampliﬁcation are incompatible. a Immunoblot of 12 cell lines. Boxes indicate ATRX-mutant lines. b Immunoblot for
HeLa cells transfected with sc-shRNA or ATRX-speciﬁc shRNAs. The fraction of ATRX relative to sc-shRNA is indicated. c Bar plot of the number of
colonies/well (mean of duplicates) after transfection of shRNAs, normalized to the sc-shRNA (dashed line). d Photograph of cresyl violet-stained colonies
after transfection with shRNAs and bar plots of the average number of colonies/well. e Map of two gRNAs targeting ATRX. f Plot of the mutation frequency
for gRNA-2, deletions (green) and insertions (red). g Bar plot of the proportion of ATRX-mutant alleles (100,000× coverage/sample). h Immunoblot for
the cell lines with the doxycycline-inducible MYCN expression construct. Numbers indicate MYCN/GAPDH ﬂuorescence intensity. The experiment was
done three times with similar results. i Line graphs of the growth curves (mean ± SD) for each cell line ± doxycycline, n = 3. j Colony assay for
SKNBE2MYCN and SKNMMMYCN cells ± doxycycline, the experiment was repeated twice with similar results. k Brightﬁeld micrograph of SKNMMMYCN
cells after 8 days in culture ± doxycycline, the experiment was repeated twice with similar results. l Brightﬁeld micrographs of three individual
SKNMMMYCN cells ± doxycycline at indicated timepoints, relative to the starting point of the movies (6 days + doxycycline), 44 cells were analyzed.
m Immunoblots of SKNMMMYCN cells without doxycycline or after 2, 4, or 45 days in culture. The escapers are pools of cells that grew in the presence of
doxycycline (n = 4). PCR for MYCN transgene and a control locus (RPL0) is indicated in the lower portion. n Xenogen image of a mouse with an orthotopic
neuroblastoma tumor (photograph), that arose from a 1:1 mixture of SKNMMMYCN cells and SKNMMCONT–Luc:YFP cells (n = 5). o Line graph of xenogen
image data described in n. p Xenogen image of a mouse with an orthotopic neuroblastoma tumor (photograph), that arose from a 1:1 mixture of
SKNMMMYCN–Luc:YFP cells and SKNMMCONT cells (n = 5). q Line graph of xenogen image data described in p. Scale bars: k, 10-μm. DOX doxycycline, IFD
in-frame deletion, sc scrambled.

SKNMMCONT cells in vivo, as determined by xenogen and
ultrasound (Fig. 2n–q).
The epigenomic landscape of MYCN-ampliﬁed and ATRXmutant NB. MYCN is a global transcriptional regulator that
activates and represses genes controlling cell division, cell size,
and cell differentiation during development19. MYCN can change
gene expression by modifying the epigenetic status of target
genes19. To analyze the epigenomic landscape in ATRX-mutant
neuroblastoma cells, compared with that in wild-type ATRX
neuroblastoma, we selected eight cell lines that encompass the
major genetic groups, including those with MYCN ampliﬁcation
or ATRX mutations (Fig. 3a). We also included eight orthotopic
patient-derived xenografts (O-PDXs) that were derived by paraadrenal injection of patient tumors into immunocompromised
mice as described previously20,24 (Fig. 3a). One of those O-PDXs
(SJNBL047443_X1) has an ATRX in-frame deletion (Fig. 3b, c
and Supplementary Data 2). Autopsy tumor material from a
patient with ATRX-mutant neuroblastoma (SJNBL030014_D)
was also included (Fig. 3a and Supplementary Data 2). We performed whole-genome bisulﬁte sequencing (WGBS; Supplementary Fig. 5 and Data 5), RNA-sequencing, and ChIP-seq of eight
histone marks (H3K4me1, H3k4me2, H3K4me3, H3K27me3,
H3K27Ac, H3K36me3, H3K9/14Ac, and H3K9me3), CTCF,
BRD4, and RNA polymerase II (PolII) across all eight cell lines,
the eight O-PDX tumors, the autopsy sample, and normal
fetal adrenal medulla. We also performed MYCN ChIP-seq
on three O-PDXs with MYCN ampliﬁcation (SJNBL046_X,
SJNBL012407_X1, and SJNBL013762_X1) and the SKNFIMYCN,
SKNBE2MYCN, and SKNMMMYCN cell lines with doxycycline on
Day 4 in culture as well as matched controls. To relate gene
expression changes to epigenetic changes induced by MYCN, we
performed ChIP-seq for the eight histone marks, CTCF, Brd4,
and RNA PolII in the SKNMMMYCN cells ± doxycycline on Day 4
in culture.
To deﬁne the chromatin states and analyze the transitions thereof
across the genome, we performed chromatin Hidden Markov
Modeling (ChromHMM) using all 393 ChIP-seq data sets (Fig. 3d, e
and Supplementary Data 6). To share these data, we have developed
a cloud-based viewer (https://pecan.stjude.org/proteinpaint/study/
mycn_nbl_2018). We identiﬁed 394 genes that were upregulated
and 544 that were downregulated 4 days after adding doxycycline to
the SKNMMMYCN or U2OSMYCN cell lines (Supplementary Data 7).
Gene set-enrichment analysis of the upregulated genes identiﬁed
MYC and MYCN targets as the most-enriched data sets
(Supplementary Fig. 6A): 84% of the upregulated genes and 42%
of the downregulated genes had a MYCN-binding site based on
6

MYCN ChIP-seq for SKNMMMYCN cells in the presence of
doxycycline (Supplementary Fig. 6B-E and Data 7). Analysis of the
chromHMM for the upregulated MYCN targets showed that
expansion of state 13 (strong transcribed gene body) downstream of
the transcriptional start site was the most signiﬁcant change (Fig. 3f,
g and Supplementary Data 7). This is consistent with previous data
showing that MYC regulates RNA PolII pause release not
transcriptional initiation25. These upregulated target genes are
enriched for the pathways involved in metabolism (e.g., SLC3A2,
SLC7A5) and mitochondrial gene expression (e.g., PNPT1) (Fig. 3f,
g, Supplementary Fig. 6B-E, and Data 7), consistent with previous
studies, demonstrating that elevated MYC/MYCN induces metabolic reprogramming in cancer cells11.
Metabolic reprogramming induced by MYCN. One form of
metabolic reprogramming induced by MYC/MYCN is glutamine
addiction26. The glutamine transporter (SLC1A5) involved in glutamine uptake and the bidirectional transporter (SLC7A5–SLC3A2)
involved in glutamine efﬂux coupled with essential amino acid
import are direct targets of MYCN and are upregulated in
SKNMMMYCN cells in the presence of doxycycline (Fig. 3g, Supplementary Data 7 and 6D, E)27. Following MYCN induction, we
quantiﬁed glutamine metabolism in SKNMMMYCN cells ± doxycycline on Day 4 in culture and measured eight tricarboxylic acid
(TCA) cycle cellular metabolites28. The proportions of ﬁve carbonlabeled glutamate and α-ketoglutarate increased, consistent with
glutamine utilization for the TCA cycle as well as reductive carboxylation to produce ﬁve carbon-labeled citrate (Fig. 4a, b).
Inefﬁcient use of glutamine and/or glucose by cancer cells can
lead to the export of glycolytic intermediates such as lactate29.
The pH of the medium was quickly acidiﬁed in subconﬂuent
cultures of SKNMMMYCN or U2OSMYCN cells in the presence of
doxycycline; however, SKNBE2MYCN and SKNFIMYCN cells
showed no difference in the pH of their media (Fig. 4c, d). The
reduced pH correlated with an increase in lactate in the culture
medium and dependence on glutamine for survival (Fig. 4e and
Supplementary Fig. 7A). To provide additional data on the
metabolic reprogramming induced by MYCN in ATRX-deﬁcient
cells, we performed a more-comprehensive metabolomic proﬁling
of 54 metabolites using 13C-labeled glucose and 13C-labeled
glutamine (Fig. 4f, g and Supplementary Data 8). Glucose was the
major source of lactate; relatively few of the carbons from glucose
were used for the TCA cycle (Fig. 4f, g and Supplementary
Data 8). In contrast, glutamine was converted to α-ketoglutarate
for the TCA cycle and reductive carboxylation.
Glutamine is also an important mitochondrial substrate; cells
must precisely balance the expression and activity of proteins
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encoded by the nucleus with those encoded by the mitochondria
to maintain homeostasis28. Cells also upregulate pathways
required to mitigate the ROS that are a natural byproduct of
mitochondrial metabolism to prevent excessive protein or DNA
damage. For example, glutamine uptake in cancer cells can elevate
glutathione levels because glutamine is converted to the
glutathione precursor, glutamate30. Cell lines that were sensitive
to glutamine depletion in the medium also had signiﬁcantly

elevated levels of glutathione (Supplementary Fig. 7B). ROS and
DNA damage were increased in the absence of glutamine
(Supplementary Fig. C, D).
Pathways involved in mitochondrial homeostasis were upregulated
in SKNMMMYCN or U2OSMYCN cells in the presence of doxycycline
(Supplementary Data 7). Little change in mitochondrial mass was
measured using MitoTracker Green in SKNMMMYCN or U2OSMYCN
cells ± doxycycline, but the mitochondrial membrane potential (Δψm)
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Fig. 3 Transcriptional and epigenetic changes induced by MYCN in ATRX-deﬁcient neuroblastoma cells. a Heatmap of the mutations in the O-PDXs and
cell lines used in this study. An autopsy sample was also used for molecular proﬁling. b Micrographs of histologic analysis of the ATRX-mutant
neuroblastoma O-PDX and corresponding patient tumor. c Plot of sequence read depth from Illumina sequencing for the ATRX gene in the patient’s
germline (blue) and tumor (red), showing somatic deletion of exons 2–11. d Heatmap of the chromHMM states used in this study with functional
annotation. e ChromHMM plot of the DIRAS1 gene and a bar plot of the gene’s expression on the right. DNA methylation and H3K27me3 and H3K4me3
ChIP-seq for DIRAS1 for a MYCN-ampliﬁed tumor (SJNBL046_X1), an ATRX-mutant tumor (SJNBL047443_X1), and fetal adrenal medulla. f ChIP-seq tracks
for a portion of the SLC3A2 gene spanning the promoter in SKNMMMYCN cells in the presence or absence of doxycycline after 4 days in culture. Dashed
line indicates the start of transcription. The scales are indicated on the right. g ChromHMM and ChIP-seq for MYCN and RNA PolII for a portion of the
SLC3A2 gene spanning the promoter in SKNMMMYCN cells in the presence or absence of doxycycline after 4 days. The dashed lines indicate the region
with induction of ChromHMM state 13 that is expanded after MYCN binds the promoter. ChromHMM chromatin Hidden Markov Modeling, FPKM
fragments per kilobase of transcript per million mapped reads, O-PDX orthotopic patient-derived xenograft.

measured with tetramethylrhodamine-ethyl ester (TMRE) was
signiﬁcantly lower in the presence of doxycycline (Fig. 4h, i). To
assess mitochondrial function in MYCN-overexpressing SKNMM
cells, we measured the oxygen consumption rate. Induction of
MYCN in SKNMM cells decreased basal mitochondrial respiration
and respiratory reserve capacity, relative to that seen in un-induced
SKNMM cells (Fig. 4j, k and Supplementary Fig. 8). Transmission
electron micrographs showed that SKNMMMYCN cells in the
presence of doxycycline had more disrupted mitochondria on Day
4 and subsequent timepoints than did SKNMMMYCN cells
maintained in culture without doxycycline or the other cell lines
(Fig. 4l–o, Supplementary Fig. 9). Similar results were obtained for the
ATRX-deﬁcient U2OSMYCN cells but not ATRX-wild-type SKNBE2MYCN cells (Supplementary Fig. 9).
Replicative stress in ATRX-mutant neuroblastomas expressing
MYCN. The mitochondrial dysfunction described above may lead
to the accumulation of ROS and in turn contribute to replicative
stress through DNA damage. The ROS increase began at Day 4
and persisted until Day 6 in SKNMMMYCN cells in the presence
of doxycycline (Fig. 5a). This was accompanied by increased
expression of γH2AX protein, a biomarker for DNA doublestrand breaks (Fig. 5b, c). Spectral karyotyping showed a signiﬁcant increase in cells with DNA fragmentation and translocation in the SKNMMMYCN cells in the presence of doxycycline
(Fig. 5d). We also detected increased DNA fragmentation in
SKNMMMYCN and U2OSMYCN cells in the presence of doxycycline by using a single-cell gel electrophoresis assay (Fig. 5e–g).
Cells with DNA-replicative stress are sensitive to hydroxyurea31.
Thus, we maintained SKNMMMYCN cells cultured ± doxycycline
with different concentrations of hydroxyurea (12.5, 25, 50, or 100
μM on Days 1–4) and measured cell viability using CellTiter-Glo on
Day 4. The SKNMM cells expressing MYCN were signiﬁcantly
more sensitive to hydroxyurea at 50 or 100 μM concentrations
(Supplementary Fig. 10A). The DNA content in each cell line,
±doxycycline at Day 4 in culture, showed an increase in S and G2/
M phases in the SKNMMMYCN cells in the presence of doxycycline,
which was consistent with cell cycle arrest as a result of DNA
damage (Supplementary Fig. 10B). The ROS scavenger N-acetyl
cysteine had a small but reproducible effect on reducing cell death
induced by ectopic MYCN expression in SKNMM cells (Supplementary Fig. 10C, D).
To identify other pathways that may modulate to MYCNinduced cell death in ATRX-deﬁcient cells, we performed a
dose–response screen using two drug libraries. The ﬁrst was a
collection of 177 oncology drugs and compounds in late clinical
development (Phase II or later). The second was a customized
library of 34 drugs and compounds that target proteins or
pathways that have been reported to reduce MYC/MYCN
oncogenic activity (Data S9). Within the oncology drug set, 37
compounds selectively potentiated killing of SKNMMMYCN cells
8

in the presence of doxycycline (Supplementary Data 9); the
majority (59.4%, 22/37) were drugs that induce DNA damage,
inhibit DNA repair or replication, or inhibit cell cycle checkpoints
(Supplementary Fig. 10E–G and Data 9). The only two drugs that
partially rescued the cell death were a third-generation retinoid
derivative (bexarotene) and an mTORC1/2 inhibitor (INK128)
(Supplementary Fig. 10H and Data 9). The bexarotene result was
particularly interesting because retinoids are an effective treatment for neuroblastoma (i.e., they reduce MYCN expression and
induce differentiation). These results were independently validated using retinoic acid (Fig. 5h, i).
Together, these data suggest that MYCN induction causes
metabolic reprogramming and mitochondrial dysfunction that
contribute to increased ROS and DNA-replicative stress. It may
be synthetically lethal in ATRX-mutant cells because they already
have DNA-replicative stress in part owing to reduced ability to
resolve G4 DNA structures. A subset of genes that are normally
induced in MYCN-ampliﬁed neuroblastomas also may have failed
to be activated in the ATRX-mutant neuroblastomas owing to the
DNA and/or histone modiﬁcations. We identiﬁed one gene that
met those criteria. CUX2 encodes a homeodomain protein with
three CUT repeats that is expressed in the developing nervous
system and important for the repair of oxidative DNA damage32.
CUX2 is a direct MYCN target and is upregulated in MYCNampliﬁed neuroblastomas but not ATRX-mutant neuroblastomas
(Fig. 5j). The CUX2 promoter is epigenetically repressed by
H3K27me3 in ATRX-mutant neuroblastomas and not induced in
SKNMM cells in the presence of doxycycline (Fig. 5j). There was
a partial rescue of cell death in SKNMMMYCN cells in the
presence of doxycycline when CUX2 was ectopically expressed
(Fig. 5k), suggesting that CUX2 is important for oxidative stress
in MYCN-ampliﬁed neuroblastomas. CUX2 is not induced by
retinoic acid in 11 different NB cell lines (Supplementary Fig. 11
and Data 10) so the mechanism of partial rescue by retinoic acid
is distinct from that of CUX2. Combining NAC with ectopic
expression of CUX2 did not signiﬁcantly increase survival over
NAC or CUX2 alone (Supplementary Fig. 11B).
Heterochromatic H3.3 deposition is altered in ATRX-mutant
NB. ATRX has an important role in H3.3 deposition in chromatin33. In addition to telomeres and pericentric heterochromatin,
ATRX helps to resolve G-quadruplex (G4) structures in the DNA
by deposition of H3.3 at those sites across the genome5,33. This is
important because G4 structures can inhibit DNA replication and
transcription33,34. G4 structures often overlap with noncanonical
DNA:RNA hybrids called R-loops because both structures are
favored in G-rich regions of the genome under negative torsional
tension (e.g., active promoters)35,36. In cancer cells, R-loops can
contribute to DNA breaks and genome instability37,38. To determine whether the pattern of H3.3 deposition is altered in ATRXmutant NB, we performed CUT&RUN39–41 on six NB cell lines
divided into three groups: MYCN-ampliﬁed cells (SKNBE2 and
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DNA sequences that are predicted to form G4 structures and 70%
(12,932) of those are predicted to form R-loops42. As expected,
there were fewer H3.3 peaks in the ATRX group and nearly a
twofold reduction in H3.3 peaks overlapping G4 sequences
(Fig. 6a). For every H3.3 peak in the data set, we assigned it to a

NATURE COMMUNICATIONS | (2020)11:913 | https://doi.org/10.1038/s41467-020-14682-6 | www.nature.com/naturecommunications

9

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14682-6

Fig. 4 Expression of MYCN in ATRX-mutant cells leads to metabolic reprogramming and mitochondrial dysfunction. a Simpliﬁed drawing of the TCA
cycle and reductive carboxylation, blue circles: 13C derived from 13C5-glutamine. b Bar plot (mean of two technical replicates) of 13C-labeled isotopomers in
SKNMMMYCN cells on day 4 ± doxycycline after 5 h of labeling with 13C5-glutamine. The arrows indicate an increase in M + 5 glutamate and M + 5 αketoglutarate (the most abundant and direct derivatives of 13C5-glutamine) in the presence of doxycycline. c Photograph of culture media on day 3 ±
doxycycline. d Line plots of media pH ± doxycycline for each day. The culture media were changed on Day 3. e Histogram (mean of two biological
replicates) of the levels of lactate at Day 4 in SKNMMMYCN cells ± doxycycline. f Simpliﬁed drawing of the glycolysis highlighting the production of lactate
from 13C6-glucose. g Bar plots of 13C-labeled isotopomers of lactate and α-ketoglutarate in the medium or cells after 18 h of labeling with 13C6-glucose or
13C -glutamine, respectively, at Day 4 in SKNMMMYCN cells ± doxycycline, with concentrations indicated on the bars. h, i Box and Whiskers plots of
5
MitoTracker Green (H) and TMRE (I) staining ± doxycycline on Day 4. Each Box shows the 10th to 90th percentiles range of data (at least 15,000 cells),
the line represents the median and the Whiskers show the minimum and maximum data range. P values were calculated using two-tailed Mann–Whitney
non-parametric test. j, k Representative results of oxygen consumption rate (OCR) and extracellular acidiﬁcation rate (ECAR) (mean and SEM of three
technical replicates) for 2.5 × 104 SKNMMMYCN cells grown under the Mito-Stress assay conditions for the Seahorse. The experiment was done three
times with similar results. l–o Representative electron micrograph of mitochondria from SKNMMMYCN cells after 4 days ± doxycycline l, n showing
disruption in the mitochondrial cristae (arrows). Bar plot of scoring of mitochondrial morphology for the SKNMMMYCN cells ± doxycycline, numbers of
scored mitochondria are indicated m, o. P value was calculated using Chi-square test. DOX doxycycline, FCCP carbonyl cyanide-p-triﬂuoromethoxy
phenylhydrazone, Olig oligomycin, Rot/AA rotenone/antimycin A, TCA tricarboxylic acid, TMRE tetramethylrhodamine ethyl ester.

group deﬁned by the pattern across the samples (ATRX, MYCN,
and WT). The constitutive (C) group includes H3.3 peaks found at
the same location across all samples (ATRX, MYCN, and WT)
(Fig. 6b). The enriched (E) group includes H3.3 peaks that are
higher in ATRX than MYCN and WT (Fig. 6b). The depleted (D)
group includes H3.3 peaks that are lower in ATRX than in MYCN
and WT and the overlapping (O) group has peaks in ATRX and
either MYCN or WT (Fig. 6b). The D group was the largest
(Fig. 6b) and 2428 of those had a correlation between ChromHMM
state and the presence or absence of H3.3 peaks; 514 (21%) had
G4 sequences and 69% of those (357) were predicted to form Rloops. The majority of H3.3 peaks that were depleted in ATRXmutant NB relative to MYCN and WT that had a correlation with
ChromHMM state were in enhancers, whereas those with
G4 sequences (and R-loops) were in promoters (Fig. 6c). For both
the non-genic and genic regions, there was a shift from active
euchromatic states (states 1–4) to inactive heterochromatic states
(states 15–17) in the ATRX group relative to MYCN and WT
(Fig. 6d–h). There was overlap between H3.3 peaks and CTCF sites
(state 18) consistent with the role of H3.3 in CTCF binding to
establish insulated chromatin domains43–45. We performed pathway analysis on the genes that had promoters or enhancers that
were depleted for H3.3 in ATRX-mutant NB and had correlation
with ChromHMM states and reduced expression in ATRX-mutant
relative to MYCN and WT. The most signiﬁcant pathways were
involved in neuronal differentiation and neural development
(Supplementary Data 11). For example, the DUSP26 gene is a
MYCN target that has G4 sequences immediately downstream of
the promoter predicted to form R-loops and selective deposition of
H3.3 in MYCN-ampliﬁed NB relative to ATRX-deﬁcient NB cells
(Fig. 6g). DUSP26 is a phosphatase that is expressed in neuroendocrine cells and can inhibit neuronal differentiation46,47. It
has also been shown to dephosphorylate and inhibit p53 in neuroblastoma cells48. We performed the same H3.3 ChIP-seq on
SKNMMMYCN with and without doxycycline and found similar
chromatin changes at MYCN target genes (Fig. 6h). Taken together,
our data show that there is marked reorganization of the chromatin
landscape in ATRX-mutant NB beyond telomeres and centromeres.
This is particularly notable at G4 sequences in promoters and
enhancers and may impact the ability of ATRX-mutant NB cells to
differentiate relative to those with wild-type ATRX.
Discussion
Mutually exclusive mutation proﬁles are not uncommon in
cancer cells; however, many are thought to result from targeting
the same oncogenic pathway49. For example, inactivation of the
RB1 tumor-suppressor gene is often exclusive of ampliﬁcation of
10

genes encoding cyclins (e.g., CCNE1) because they target the same
pathway. Examples of synthetic lethality caused by oncogene
activation and tumor-suppressor mutation are much less common, and few (if any) have been validated in vivo.
Here, we show that ampliﬁcation of the MYCN oncogene and
inactivation of the ATRX tumor-suppressor gene are mutually
exclusive in neuroblastomas from patients of all ages and stages of
disease. One discrepant tumor sample may have contained two
separate clones, but more-detailed analysis was not possible owing
to limited tissue. In mouse models and cell lines, the combination of
elevated MYCN expression and ATRX loss led to synthetic lethality.
Ectopic MYCN caused metabolic reprogramming, mitochondrial
dysfunction, ROS production, and DNA damage in ATRX-mutant
neuroblastoma cells. We propose that MYCN ampliﬁcation and
ATRX mutations are incompatible in neuroblastoma, because both
lead to DNA-replicative stress10,38,39. Consistent with this model,
the synthetic lethality was partially rescued by genes that reduce
oxidative stress (CUX2) and pharmacological agents that induce
differentiation (retinoic acid) or reduce ROS levels (N-acetyl
cysteine). Similarly, pharmacological agents that induced replicative
stress through DNA damage exacerbated the synthetic lethality.
ATRX-mutant neuroblastomas have several unique features,
relative to other ATRX-mutant cancers. First, DAXX was not
mutated in our cohort, whereas in pancreatic neuroendocrine
tumors (PanNETs), ATRX, and DAXX mutations have approximately the same frequency and are mutually exclusive50. Second,
ATRX-mutant neuroblastomas have worse outcome, but patients
with ATRX/DAXX-mutant PanNETs tumors have prolonged
survival50. Third, ATRX mutations in neuroblastomas are often
in-frame deletions that remove approximately half of the amino
terminus of the protein. In other cancers, the mutations are indels
or nonsense mutations50. In the original study describing ATRX
mutations in neuroblastoma3,16, there was no difference in outcome or clinical presentation for patients with in-frame deletions
versus missense or nonsense mutations. However, that cohort was
relatively small and a much larger study of ATRX-mutant neuroblastomas would be required to determine if there is any
genotype–phenotype correlation for the type of ATRX mutation.
Previous studies suggest that amino acids 1–841 of ATRX are
sufﬁcient for localization to heterochromatin33. This region is
deleted in the ATRXIFDs in most ATRX-mutant neuroblastomas.
The ADD domain (amino acids 168–293) binds to histone H3 tails,
with preferential binding to H3K9me3 domains that lack H3K4
methylation. HP1 can bind H3K9me3 and recruit ATRX through
the HP1-interacting domain (amino acids 586–590), even in the
absence of the ADD domain in ATRX. Therefore, in neuroblastomas with in-frame deletions, we propose that they lack the
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heterochromatin-binding domain and have defects in H3.3-chaperone function that is required for genome maintenance. Our data
also suggest that there are defects in H3.3 deposition at promoters
and enhancers for genes involved in neuronal differentiation,

particularly for those with G4 structures predicted to form R-loops.
Indeed, one of the major pathways that was deregulated is involved
in retinoic acid response. This is important because retinoic acid
induces differentiation of NB cells and is part of the treatment
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Fig. 5 Expression of MYCN in ATRX-mutant cells leads to ROS production, DNA damage, and replicative stress. a Bar plot (mean±SD) of ROS levels on
Day 6 ± doxycycline. P value was calculated using two-tailed Student t test. b Immunoblots on Day 4 ± doxycycline. The experiment was repeated with the
same results. c Immunoﬂuorescent detection of γH2AX (red) and nuclei (blue) in SKNMMMYCN cells on Day 4 ± doxycycline. The experiment was
repeated with the same results. d Spectral karyotype analysis (SKY) of SKNMMMYCN cells ± DOX on Day 8. Chromosomes are shown adjacent to the
pseudo-colored representation. Arrows indicate translocations. The pie charts show the proportion of cells with DNA fragmentation (n = 50). P value was
calculated using Chi-square test. e, f Micrographs of single-cell electrophoresis of individual nuclei (dashed circles) and their COMET tail (arrows) ±
doxycycline on Day 5. g Mean±SD of the COMET assay scoring. The number of analyzed cells are presented on the graph. h Photograph of cresyl violetstained colonies from SKNMMMYCN cells ± doxycycline, with increasing concentrations of retinoic acid (RA). i Immunoblots of SKNMMMYCN cells ±
doxycycline, with or without 5 μM RA. The level of MYCN protein was reduced by 30% (0.7×) in the presence of RA. j ChromHMM and ChIP-seq for
MYCN, H3K4me3, and H3K27me3 for the CUX2 promoter for a MYCN-ampliﬁed neuroblastoma (SJNBL012407_X1) xenograft and SKNMMMYCN cells in
the presence or absence of doxycycline after 4 days in culture. The gene expression (FPKM) is indicated, and the dashed line indicates the start of
transcription. k Line plot of SKNMMMYCN cells in the presence or absence of doxycycline after 4, 6, 8, and 10 days in culture with or without ectopic
expression of CUX2 or the GFP control from lentiviral infection. Each point is the mean and standard deviation of triplicate experiments, and the asterisks
indicate statistical signiﬁcance (P = 0.005, 0.001, and 0.008 at days 6, 8, and 10, respectively, two-tailed Student's t test). Scale bars e, f, 10 μm. DOX
doxycycline, RA retinoic acid, ROS reactive-oxygen species, m marker chromosome fragments that could not be deﬁnitively identiﬁed.

regimen for NB patients. It is possible that there may be a block in
retinoic acid response in ATRX-mutant NB cells and this may
contribute to the poor outcome for those patients.
Based on our data, we propose that ATRX mutation contributes to tumorigenesis in two ways. First, defects in H3.3
deposition at telomeres leads to telomere maintenance through
ALT. Second, ATRX mutations lead to defects in H3.3 deposition
at G4 structures in promoters and enhancers of genes involved in
neuronal differentiation including retinoic acid-responsive genes.
As a result, gene expression is attenuated and ATRX-mutant
neuroblastoma cells continue to proliferate. Although DAXX
mutations can also contribute to ALT, they do not alter H3.3
deposition at G4 structures. We propose that both mechanisms
(ALT and G4 resolution) are essential for tumorigenesis and that
is why we did not detect any DAXX mutations in our cohort.
Although the inability of ATRX-mutant neuroblastoma cells to
resolve G4 structures promotes tumorigenesis by preventing
differentiation, it also causes DNA-replicative stress and slows
tumor growth. Indeed, it was recently shown that ATRX can play
a role in suppressing R-loop (RNA-DNA hybrid) formation51. Rloops can lead to collapse of the DNA replication fork and
replicative stress52,53. This may be why ATRX-mutant neuroblastomas are slow growing and indolent. DNA-replicative stress
leads to synthetic lethality with ectopic MYCN expression. This
genetic synthetic lethality may eventually be exploited in the
clinic by reducing the function of ATRX in patients with MYCNampliﬁed tumors or inducing metabolic (or other changes)
caused by MYCN expression in ATRX-mutant tumors. To
achieve this ambitious goal in high-risk neuroblastoma, much will
need to be learned about the downstream targets of ATRX and
MYCN that contribute to this phenotype.
Methods

Uncropped blots and ﬂowcytometric analysis gating. All uncropped gels and
blots are shown in Supplementary Fig. 12. Flow cytometric analysis gating information is shown in Supplementary Fig. 13.
Patient samples. Patients were eligible for inclusion in the analytic cohort if they
enrolled in the COG Neuroblastoma Biology study ANBL00B1 before treatment;
had a conﬁrmed diagnosis of neuroblastoma; and had reported outcome data.
Informed consent of the patients and/or parents/legal guardians was obtained at
the time of enrollment to ANBL00B1. Detailed description of the statistical analysis
is provided in the supplemental information.
Statistical analysis of ATRX mutations and clinical features. The cohort used in
this analysis consists of 477 neuroblastoma patients (of which 476 had clinical data
and 475 had outcome data available) representing a mixture of risk levels, disease
stages, and ages at diagnosis. All are enrolled on COG protocol ANBL12B8
(“Analysis of ATRX Mutations in Neuroblastoma”) and were assayed for ATRX
12

mutations. Roughly 80% of the patients were diagnosed between 2010 and 2012,
with the remaining 20% diagnosed between 2001 and 2009.
The frequency of ATRX mutations, along with Clopper–Pearson exact 95%
conﬁdence intervals, were calculated across the entire cohort and in subgroups
formed by the combination of age categories (12 yrs at diagnosis) and INSS stage
categories (1, 2 A/B or 3, 4 S, and 4). Chi-square tests or Fisher’s exact tests,
depending on sample size, were used to test for associations between ATRX
mutations and clinical factors. EFS and OS were compared between patients with
vs. without ATRX mutations, across the entire cohort and in subgroups based on
stage, age, and risk. EFS and OS Cox models were used to assess the prognostic
strength of ATRX mutations in the presence of standard clinical risk factors.
A forward-selection process was used to construct parsimonious Cox models. At
the beginning of the forward-selection process, the following candidate variables were
considered to be on equal footing: age at diagnosis (< 18 months vs. > 18 months)
INSS stage (non-stage 4 vs. stage 4), sex, MYCN status (non-ampliﬁed vs. ampliﬁed),
ALK mutation, ploidy (hyperdiploid vs. diploid), 1p (no LOH vs. LOH), 11q (no LOH
vs. LOH), INPC histology (favorable vs. unfavorable), ATRX mutation,
mitosis–karyorrhexis index (MKI, low/intermediate vs. high), and grade (totally
undifferentiated/poorly differentiated vs. differentiating). Variables were entered into
the model one at a time, with the variable chosen for entry being the one that is most
signiﬁcant at each step, per a Wald test. If at any point in the process histology was
chosen to enter the model, then MKI, grade, and age at diagnosis were no longer
considered for entry, as histology is confounded with these variables. Conversely, if at
any point MKI, grade, or age at diagnosis entered the model, then histology was no
longer considered for entry. The selection process ended when all remaining
candidate variables failed to reach signiﬁcance at the 0.05 level.
EFS time was measured as the number of days from diagnosis to date of relapse,
disease progression, secondary malignancy, death, or, if no event occurred, date of last
contact. OS time was measured as the number of days from diagnosis to date of death,
or, if the patient did not die, date of last contact. MYCN ampliﬁcation status was
assessed both by the neuroblastoma reference lab as part of ANBL00B1 enrollment
and by St. Jude Children’s Research Hospital. There were some discrepancies between
the two, particularly in one patient with an ATRX mutation (an aberration which
previous research suggests is mutually exclusive from MYCN ampliﬁcation), whom
the six neuroblastoma reference lab determined to have MYCN ampliﬁcation, whereas
St. Jude detected no ampliﬁcation. Owing to these discrepancies, both sets of MYCN
ampliﬁcation data were considered individually in this analysis.
Outcome was not compared in the <18 months old at diagnosis subgroup, as
there were no patients with ATRX mutations in that subgroup. Nor was outcome
compared in the 18 mo–5yrs old at diagnosis subgroup, as only one patient in that
subgroup had an ATRX mutation.
The median follow-up time for patients who did not have an event was 3.9 years.
The median follow-up time for patients who did not die was also 3.9 years. The
forward-selection process substituting MYCN ampliﬁcation data from Dr. Federico’s
lab for those from the NBL reference lab yielded the same ﬁnal EFS and OS Cox
models. The effect of ATRX mutations on outcome was also tested among patients
with INSS stage 4 disease who were at or above 5 years of age at the time of diagnosis.
This subgroup was of interest because of its association with a chronic/indolent course
of disease. A notable difference between this subgroup and the subgroups in which
signiﬁcant associations between outcome and ATRX mutation were observed, was the
number of patients with high-risk disease; the subgroup of older INSS stage 4 patients
was entirely high risk, whereas the other subgroups included a mixture of risk levels.
This prompted us to perform a subgroup analysis based on risk group (high vs. low/
intermediate). There were ﬁve low/intermediate risk patients with ATRX mutations,
two of which experienced an event and one subsequently died. The differential effect
of ATRX mutations between high- and non-high-risk disease groups was also detected
in the Cox model of EFS that included an interaction term for mutation and risk level.
Mutual exclusivity between ATRX mutations and MYCN ampliﬁcation in
neuroblastoma was done by merging the COG, TARGET, and PCGP data.
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Custom capture for ATRX, MYCN and ARID1A/B. Targeted enrichment was
performed using the Seqcap EZchoice Kit (Roche) according to vendor instructions
for the Kapa workﬂow with 500 ng of genomic DNA as the starting input for
library construction.
Exome sequencing. Whole-exome sequencing was conducted using the SeqCap
EZ HGSC VCRome (Roche) according to manufacturers' instructions.
MYCN FISH. Puriﬁed human NMYC BAC DNA (RP11-1183P10) was labeled with
a red-dUTP (AF594, Molecular Probes) and human chromosome 2 control

(2q11.2) BAC DNA (RP11-527J8) was labeled with a green-dUTP (AF488,
Molecular Probes) both by nick translation. The parafﬁn slides were deparafﬁnized
with xylene 2 × 10 min each at room temperature (RT), placed in ethyl alcohol 3 ×
2 min each at RT, air-dried, placed in 10% buffered formalin for 1 h at RT. The
slides were then placed in pepsin (8 mg/ml) in 0.1 N HCL for 3 min, rinsed in dH2O
for 5 min at RT. One-hour incubation in Carnoy’s ﬁxative at RT was performed.
The labeled probes were combined with human sheared DNA and hybridized to
the slides in a solution containing 50% formamide, 10% dextran sulfate, and 2×
SSC. The probe and slide were co-denatured at 90 °C for 12 min and incubated
overnight at 37 °C on a Thermobrite. In brief, washed in PN and then stained with
4,6-diamidino-2- phenylindole (DAPI) (1 µg/ml). Images were captured using a
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Fig. 6 H3.3 deposition is altered at G4 sequences in ATRX-mutant neuroblastomas. a Stack bar plot of H3.3 peaks in the ATRX-deﬁcient (CHLA90,
SKNMM), MYCN ampliﬁed (SKNBE2, IMR32), and ATRX wild type, MYCN non-ampliﬁed (LAN6, SKNFI) cell lines. The H3.3 peaks that overlap with
G4 sequences are shown in gray. b Stack bar plot of H3.3 peaks that are constitutive (C) across all three groups (ATRX, MYCN, WT), enriched (E) in ATRX
mutant, depleted (D) in ATRX mutant, or overlap (O) between ATRX mutant and MYCN or WT. The H3.3 peaks that overlap with G4 sequences are
shown in gray and the number of peaks for the D group are shown. c Piechart of the location of D group H3.3 peaks that have a correlation between the
presence or absence of an H3.3 peak and ChromHMM state. Separate pie charts are shown for those that overlap with G4 sequences and those that lack
G4 sequences. d Heatmap of the ChromHMM states used in this study with color coding. e Stack bar plot of the distribution of ChromHMM states for each
cell line in the non-genic regions that have D group H3.3 peaks that correlate with ChromHMM state and overlap with G4 sequences or lack f
G4 sequences. g ChromHMM, WGBS, and ChIP-seq tracks for the DUSP26 gene in SKNMM (ATRX mutant) and SKNBE2 (MYCN ampliﬁed) cells. Gene
expression is indicated (FPKM) and G4 motif sequences are shown below the ChromHMM tracks. h ChromHMM, WGBS, and ChIP-seq tracks for the
SLC3A2 gene in SKNMMMYCN cells with and without doxycycline. Gene expression is indicated (FPKM) and G4 motif sequences are shown below the
ChromHMM tracks. DOX doxycycline, ChromHMM chromatin hidden markov modeling, G4 guanine quadruplex structure.

Table 2 Numbers of enrolled mice for neuroblastoma genetic
mouse model survival study.
Strain

Enrolled

MYCN
MYCN-ATRX
MYCN-ALK
MYCN-ALK-ATRX

45
59
18
47

Did not reach
the survival age
8
13
1
12

Censored
1#
2##
0
8*

Reported in the
survival analysis
36
44
17
27

#Found dead no tumors.
##Hunched and lethargic

no tumors, large spleen.
*Malocclusion, four mice with ﬁght wounds, paralysis hind limbs, found dead no tumors, large
thymus (dyspnea).

Plan-Apochromat × 63 objective on a Zeiss Axio Imager.Z2 microscope and
GenASIs scanner (ScanView software version 7.2.7).
ATRX IHC. ATRX immunohistochemistry was done on formalin-ﬁxed 4-μm-thick
parafﬁn sections using Leica Polymer Reﬁne Detection kit (Leica Microsystems,
Wetzlar, Germany) on a Leica Bond system. Epitope retrieval was done by heating
and anti-ATRX antibodies polyclonal antibodies (1:600; Sigma-Aldrich) was used
and incubated for 15 min3.
Histopathologic review of genetically engineered mouse models. Adrenals and
paravertebral sympathetic ganglia from Atrxﬂox-LSL-MYCN:Dbh-iCre mice at the
age of three weeks and 1 year by hematoxylin and eosin (HE) staining and
immunohistochemical staining for Ki-67, cleaved caspase 3, tyrosine hydroxylase,
and synaptophysin. Formalin-ﬁxed adrenal glands and sympathetic ganglia were
processed and embedded in parafﬁn by standard techniques, sectioned at 4 μm,
mounted on positively charged glass slides (Superfrost Plus; Thermo Fisher Scientiﬁc, Waltham, MA), and dried at 60 °C for 20 min. Tissue sections were then
stained with H&E or subjected to immunohistochemical (IHC) staining. For IHC,
tissue sections underwent antigen retrieval in a prediluted Cell Conditioning
Solution (CC1; Cat# 950-124; Ventana Medical Systems, Indianapolis, IN) for 32
min on a Discovery Ultra immunostainer (Ventana Medical Systems, Tucson, AZ)
in order to detect tyrosine hydroxylase, synaptophysin, or Ki-67 antigen. The
primary antibodies used in this study included the following: A rabbit polyclonal
antibody raised against tyrosine hydroxylase diluted 1:500 (cat# AB152, EMD
Millipore, Billerica, MA); a rabbit polyclonal antibody to synaptophysin diluted
1:400 (cat# ab7837; Abcam, Cambridge, UK); and a rabbit monoclonal antibody to
Ki-67 antigen (Clone SP6) diluted 1:50 (cat# RM-9106-S; Thermo Scientiﬁc, Fremont, CA). Binding of these primary antibodies was detected using OmniMap
anti-Rabbit (#760-4311; Ventana Medical Systems), with DISCOVERY ChromoMap DAB Kit (Ventana Medical Systems) as chromogenic substrate. Stained sections were examined by a pathologist blinded to the experimental group
assignments.
Orthotopic patient-derived xenografts. Mouse studies were performed in a strict
accordance with the recommendations in the Guide to Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee (IACUC) at St. Jude Children’s
Research Hospital. All efforts were made to minimize suffering. All mice were
housed in accordance with approved IACUC protocols. Animals were housed on a
12–12 light cycle (light on 6:00, off 18:00) and provided food and water ad libitum.
Patient-derived xenograft cells were generated and maintained orthotopically in
athymic nude (Jackson Laboratories, strain code 007850), NSG (Jackson
Laboratories, strain code 005557) or C57BL/6 scid mice (Jackson Laboratories,
strain code 001913) as described previously54. Tumor cells were dissociated using
14

Trypsin (10 mg/ml, Sigma Cat # T9935) ﬁltered and then suspended in a Matrigel
basement membrane matrix (BD Biosicences catalog number 354234) at a
concentration of 2 × 105 cells per 10-μl and placed on ice for injection. The cells
were injected in the para-adrenal region of the mice with ultrasound guidance
under anesthesia.
Genetic mouse models. To test the incompatibility between ATRX mutations and
MYCN overexpression in mice, we used LSL-MYCN:DbhiCre mice17. These mice
express MYCN from the Rosa26 locus when a stop sequence is ﬂoxed out by Cre
recombinase under the control of Dbh promoter in sympathetic ganglion cells. We
breed LSL-MYCN:DbhiCre mice to AtrxFlox mice8 to inactivate Atrx in the same
tissues. We also tested the consequences of Atrx inactivation when Th-ALKF1174L
allele is added18 (LSL-MYCN: DbhiCre:Th-ALKF1174L). Th-ALKF1174L mice constitutively express ALKF1174L, the most common activating ALK mutation found in
human neuroblastoma, under the control of Th promoter.
Mice were genotyped using the published protocols8,17,18. Mice with the desired
genotypes were enrolled in the study at the time of weaning and were followed up
by abdominal palpation at least once every 2 weeks starting from age of 6 weeks
(Table 2). Enrolled mice that died with no detectable tumors were censored out of
the survival study. Mice were killed when the tumor is 20% of body weight or when
the mouse has other morbidities, e.g., lethargic, hunched or dehydrated. After
euthanasia, mice were opened longitudinally to expose abdomen, thorax, and neck
to search for tumors. Tumors were dissected out and were cut into pieces for
histological, immunohistochemical, DNA, RNA, and protein preparations.
Whole-genome sequencing. DNA from the tumors and matching germline
samples was sequenced and analyzed as described previously54. In brief, 250–500
ng of genomic DNA was input for library construction using Illumina-compatible
adapters, and four to six cycles of ampliﬁcation were performed with KAPA HiFi
Hotstart ReadyMix (KAPA Biosystems). The reference human genome assembly
NCBI Build 37 was used for mapping samples. WGS mapping, coverage and
quality assessment, single-nucleotide variation (SNV)/indel detection, tier annotation for sequence mutations, and identiﬁcation of LOH have been described
previously55. Structural variations were analyzed and annotated using CREST56.
Copy number variations were identiﬁed by evaluating the difference of read depth
for each tumor and its matching normal using CONSERTING57. WGS data were
uploaded at EMBL with accession number EGAS00001002528.
CUT&RUN and analysis. We did automated CUT&RUN (AutoCUT&RUN) for
H3.3 as described in detail https://www.protocols.io/view/autocut-run-genomewide-proﬁling-of-chromatin-pro-ufeetje. In brief, cells were bound to concanavalin
A-coated magnetic beads (Bangs Laboratories), permeabilized with digitonin and
then incubated with primary antibody against H3.3 (Abnova, clone 2D7-H1),
followed by incubation with rabbit anti-mouse IgG (Abcam, ab46540). Cells were
arrayed on a 96-well plate and the rest of the reaction was carried out on a
Beckman Biomek FX, including digestion with proteinA-MNase, ligation of
adapters and library preparation. Size distributions of prepared libraries were
assessed using an Agilent 4200 TapeStation. Libraries were pooled and at equimolar concentrations and 25 × 25 bp paired-end sequencing on an Illumina HiSeq
2500 was performed.
To ﬁnd differential binding sites for H3.3, for each CUT&RUN sample, we
called peaks twice by MACS2 (paired-end mode) that one using default FDR
corrected p value cutoff 0.05 as high conﬁdence peak set and the other using 0.5 as
low conﬁdence peak set. Then for each of the three groups, we compiled the
reproducible peak set that required a high conﬁdence peak also overlap a low
conﬁdence peak from the other samples within the sample group. Then we merged
the reproducible peaks from three group to create a reference peak set and counted
fragments (fragment size <2000 bp) overlap the reference peaks for each sample. At
last, we performed statically tests using Voom58. To check their overlapping with
G4 motifs and R-Loops, we downloaded G4 Motifs from supplementary data of
ref. 59 and lifted over them from hg18 to hg19, we got 100,780 regions. We
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downloaded 169,222 “RLFS in genic and proximal regions” from http://rloop.bii.astar.edu.sg/ for hg19 as predicted R-Loops regions60.
Whole-genome bisulﬁte sequencing and analysis. Genomic DNA was extracted
using the DNeasy Kit (QIAGEN #69504) according to the manufacturer’s protocol
and quantiﬁed with a Nanodrop (Thermoscientiﬁc). Whole-genomic bisulﬁte
conversion and sequencing were done by Hudson Alpha (Huntsville, AL).
Sequencing data were aligned to the hg19 human genome using BSMAP2.7461.
We ﬁrst performed statistical test of differentially methylated locus (DML) between
MYCN-ampliﬁed and non-MYCN-ampliﬁed samples using DMLtest function
(smoothing = TRUE) in DSS (Wu et al. 2015), the results were then used to detect
differentially methylated regions (DMRs) using CallDMR function in DSS, the p
value threshold for calling DMR is 0.01. The minimum length for DMR is 50 bps
and the minimum number of CpG sites for DMR is 3. The minimum methylation
difference is 0.2. The DMRs that overlap with the promoters (1 kb ﬂanking the
TSS) of differentially expressed genes (at least twofold changes and adjust p value ≤
0.1) were deemed to be associated with gene expressions.
RNA-Seq and analysis. RNA was extracted from cultured cells and tissues using
RNeasy Kit (QIAGEN #74104) or TRIzol (Life Technologies) preparations via a
phenol–chloroform extraction or Direct-zol RNA MiniPrep (Zymo Research #
R2052) following manufacturers’ protocols. RNA concentration was measured
using a NanoDrop (Thermo Fisher scientiﬁc, Waltham, MA) and the quality of
RNA was determined with a bioanalyzer (Agilent Technologies, Santa Clara, CA).
Libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit
(Illumina, San Diego, CA) from 500-ng total RNA. Paired-end deep sequencing
was done using HiSeq 2500 sequencers (Illumina, San Diego, CA).
FASTQ sequences were mapped to the human genome hg19 (GRCh37-lite) and
Gene-based FPKM quantiﬁcation was calculated similar to previously described57
using GENCODE gene annotation (v26lift37). We then used VOOM58 for
differential analysis between +DOX vs −DOX. To conﬁrm the results were
meaningful, we ranked the genes by log2 fold change and use GSEA62 to check if
any MYCN-related gene sets in MSigDB(v6.1) could be found enriched. Indeed,
WEI_MYCN_TARGETS_WITH_E_BOX63 gene set were found top enriched for
upregulated genes in +DOX (rank 46 out of 11371 gene sets, NES = 3.01, FDR
corrected p value < 1e-4).
ChIP-Seq. Antibodies used in this study to generate ChromMM were previously
validated and the validation data and protocols are available through St. Jude
Childhood Solid Tumor Network website (https://www.stjude.org/CSTN/)20.
For MYCN ChIP-Seq, we used rabbit polyclonal antibody (Active Motif Cat#
61185). This antibody was validated by small-scale and large-scale sequencing by
active motif as well as by us in St. Jude Children’s Research Hospital. We tried
different amounts of the antibodies and chromatin and determined that 20-µg of
the antibody and 200-µg of the chromatin per ChIP-Seq reaction show the best
results.
Chromatin in cultured cells was ﬁxed by changing the medium with fresh
medium containing 1% formaldehyde (Thermo scientiﬁc # 28906). Snap-freezed
xenografts were pulverized and hammered to powder in liquid Nitrogen,
suspended in PBS and ﬁxed by adding formaldehyde (Thermo scientiﬁc # 28906)
to ﬁnal concentration of 1%. Fixation was done for 10 min at room temperature.
Cross-linking was stopped by adding glycine to a ﬁnal concentration of 1.25 M.
Cells and xenografts were washed in 1× PBS containing 1× protease inhibitor
(Pierce # 78430).
Chromatin preparation and shearing were done using TruChIP chromatin
shearing kit (Covaris #520127) following the manufacturer’s protocol. Chromatin
immune-precipitation (ChIP) reactions were performed using iDeal ChIP-seq kit
(Diagenode # C01010051) with 10% of chromatin from each reaction was used as
an input. Precipitated DNA was de-crosslinked, extracted using MinElute PCRpuriﬁcation kit (QIAGEN #28006) and quantiﬁed using the Quant-iT PicoGreen ds
DNA assay (Life Technologies #Q33120). Quantitative polymerase chain reaction
(qPCR) was done to assess the efﬁciency of ChIP reactions as described in the
validation protocols. Five to ten nanograms of the input and precipitated DNA
were used to prepare the sequencing libraries using the NEBNext ChIP-Seq Library
Prep Reagent Set for Illumina with NEBNext High-Fidelity 2× PCR Master Mix
following the manufacturer’s instructions (New England Biolabs) with some
modiﬁcations as described previously;64 after adaptor ligation, 1:1 Ampure cleanup
was added twice, no Ampure size-selection step and the extension was done for 45
seconds. Inset-size distribution of the completed libraries was analyzed using a
2100 BioAnalyzer High Sensitivity kit (Agilent Technologies) or Caliper LabChip
GX DNA High Sensitivity Reagent Kit (PerkinElmer). ChIP reactions and library
preparation for RNA-Pol II, Brd4 H3K9me3 and MYCN were done by Active
Motif. Quant-iT PicoGreen ds DNA assay (Life Technologies) and Kapa Library
Quantiﬁcaiton kit (Kapa Biosystems) or low-pass sequencing on a MiSeq nano kit
(Illumina) were used to quantify the libraries. Fifty-cycle single-end sequencing was
performed on an Illumlina HiSeq 2500.
ChIP-Seq analysis. ChIP-Seq analysis was done as described previously64. In brief,
ChIP-Seq reads were aligned to human genome hg19 (GRCh37-lite) using BWA
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software (version 0.7.12-r1039, default parameter) and the duplicated reads were
marked using Picard software. We kept only non-duplicated reads for the analysis
using samtools (parameter “-q 1 -F 1024” version 1.2). The quality control of the
data followed ENCODE criteria. We calculated relative strand correlation value
(RSC) and estimated the fragment size under support of R (version 2.14.0) with
packages caTools (version 1.17) and bitops (version 1.0-6). We required at least 10
M unique reads for point source factors H3K4me2/3, H3K9/14Ac, H3K27Ac,
CTCF, RNA PolII, BRD4) with RSC > 1, 20 M unique reads for broad markers
(H3K4me1, H3K9me3, H3K27me3, H3K36me3) and 10 M unique mapped reads
for INPUTs with RSC < 1. All samples were manually inspected and the SPP
(version 1.1) was used to generate the cross-correlation plot. Then we generated
bigwig ﬁles from the best fragment size (the smallest fragment size estimated by
SPP). Bigwig ﬁles were examined using IGV genome browser for clear peaks and
low background noise. MACS2 (version 2.0.10.20131216)65 were used to call peaks
for MYCN ChIP-Seq data with FDR corrected p value 0.05 (–nomodel –extsize
FRAGMENTSIZE, where FRAGMENTSIZE was estimated by SPP as described
above). Genes promoter (TSS ±2 kb) with MYCN peaks called were considering
have MYCN-binding site. Enrichr66 were used for pathway analysis.
Super-enhancer and core regulator circuit analysis. Super-enhancers and core
regulator circuit analysis have been performed as described previously64. We called
auto-regulators by CRCMapper67 based on super-enhancers called by ROSE68. We
provided two sets of results that one only used H3K27ac data, while the other one
excluded H3K27ac peaks overlapping promoter (deﬁned by H3K4me3 peaks)
before calling super-enhancer by ROSE.
ChromHMM. ChromHMM models were generated for y as described before54. In
brief, Non-duplicated aligned reads were extended by fragment size, and
ChromHMM (version 1.10, with ‘-colﬁelds 0,1,2,5 –center’ for BinarizeBed) was
used for chromatin state modeling. To choose the state number, we ﬁrst modeled
all samples together from seven states to 33 states and selected the model with
18 states upon manual inspection. For better visualization of the dynamics of
HMM state across stages, we normalized color intensity by the maximum total
percentage of a state covering a gene and ﬂanking region. We reduced the interval
for an HMM state to half bar and the intensity to half the normalized amount if it
did not rank in the top two HMM state for a gene. As HMM states could be
assigned by multiple genes, the maximum total percentage across genes was used
for normalization.
We applied the Hidden Markov Model trained for 18 states from previously
four types of solid tumors to the data from this manuscript. Expanded
chromHMM state 13 were deﬁned as proportion of promoter downstream (TSS ~
TSS + 2 kb) in SKNMMMYCN + Dox > twofold of SKNMMMYCN − DOX and ≥
20% in SKNMMMYCN + DOX.
Immunoblotting. The medium was removed and the cells were washed twice with
PBS then the cells were scrapped in 1-ml PBS and centrifuged at 2000 × g for 5 min
at 4 °C to pellet the cells. PBS was removed and the cells were ﬂash-freezed in dry
ice and stored at −80 °C until use. Cell pellets were thawed on ice and lysed for 15
min in radioimmunoprecipitation assay buffer (Sigma Cat. #R0278) supplemented
with 1 × Halt protease inhibitor (Thermo Fischer, Cat. #7834) and 5 mM ethylenediaminetetraacetic acid (EDTA). Lysate were then centrifuged for 15 min at
15,000 rpm at 4 °C. Protein concentration in the cell lysates was measured using
BCA protein assay kit (Thermo Fischer, Cat. #232225). Equal amounts of total
protein were resolved on 4–15% sodium dodecyl sulfate polyacrylamide gel (Biorad
Cat#4561086) and transferred to a nitrocellulose membrane by electrophoresis at
30 volts overnight at 4 °C. Non-speciﬁc binding was blocked by incubating the
membrane with Odyssey Blocking buffer, PBS (LiCore Cat# 927-40000) for 1 h at
room temperature. Then the membrane was incubated with the primary antibody
overnight at 4 °C. The following antibodies were used: rabbit anti-ATRX (1:1000,
Abcam, ab97508), mouse anti-MYCN (1:1000, Santa cruz Biotechnology, sc53993), rabbit anti-GAPDH (1:2500, Abcam ab-9485), rabbit anti-DAXX (1:1000,
Santa cruz Biotechnology, sc-7152) and mouse anti-β-actin (1:5000, Sigma, A1978).
Membranes were washed three times in PBS with 0.1% Tween-20 at room temperature then were incubated in the secondary antibodies: IRDye 800CW goat antimouse (1:5000, LiCore, 925-68070) or IRDye 680CW goat anti-rabbit (1:5000,
LiCore, 925-32211) for 30 min at room temperature. The membranes were then
washed three times in phosphate-buffered saline with Tween; 5 min each at room
temperatures and one time in PBS. The membranes were then scanned by Odyssey
CLX infrared gel imaging system (Li-Cor Biosciences, Lincoln, NE). Band intensities were quantiﬁed using ImageStudio Lite software (Li-Cor Biosciences,
Lincoln, NE).
Telomere FISH. After a 5-hour colcemid incubation, cells from both samples were
harvested using routine cytogenetic methods. A commercially prepared directly
ﬂuorescein isothiocyanate-labeled PNA telomere probe (DAKO, Cat. # 5327) was
used for this analysis. DAKO protocols were followed for the pre-treatment and
hybridization steps. The slides were then stained with DAPI. In total, 255 interphase nuclei from each sample were individually analyzed for the number of
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telomeres/cell, ﬂuorescence/cell, and ﬂuorescence/telomere. A ﬁxed exposure time
is used for all cells.
Telomere qPCR. Telomere qPCR was done as described previously (Cheung
et al.3). DNA was extracted using DNAeasy Kit (Qiagen, Cat. # 69504). qPCR was
done on 10-ng DNA template using SYBR green Select master mix (Thermo Fisher,
Cat. #4472908). Two sets of primer pairs were used in separate reactions were used
to amplify the telomeric sequence and a common locus RPLP0, which was used as
an internal control. The reactions were done in duplicates and the average delta C
(t) was calculated for every sample by subtracting the average C(t) values of the
telomeric reaction from those of the internal control reactions. The primers
used are
Telomere F: 5′-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGG
TT-3′
Telomere R: 5′-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCC-3′
Control, locus:
RPL0 F: 5′-CAGCAAGTGGGAAGGTGTAATCC-3′
RPL0 R: 5′-CCCATTCTATCATCAACGGGTACAA-3′
ATRX shRNAs. Eight ATRX-speciﬁc shRNA lentiviral vectors were purchased
from Dharmacon as bacterial glycerol stocks (Cat. # V2LHS-092920 (#9), V2LHS202920 (#20), V2LHS-22887 (#22), V3LHS-375686 (#37), V2THS-22887 (#87),
V2THS-93289 (#30), V2THS-255090 (#13), and V2THS-201895 (#95)). Lentiviruses were made in HEK293T cells by co-transfecting the viral vectors with three
packaging plasmids. The supernatants containing the viral particles after 48 and 72
h were collected, ﬁltered, concentrated using ultracentrifugation, and titrated in
HeLa cells using the GFP or RFP reporters in the vector. In addition, two nonsilencing shRNA lentiviral particles were used as controls (Cat. # RHS4743 and
RHS4346). Cells were transduced with equal number of viral particles and transduced cells were selected with ﬂow cytometry or pouromycin after 48 h post
transduction.
Cell cycle analysis. Cells were trypsinized and harvested, pelleted and suspended
in 1-ml propidium iodide solution (0.05 mg/ml propidium iodide (Sigma, Cat. #
P4864), 0.1% sodium citrate, 0.1% Triton X-100). The cells were then treated with
10-ml 0.2 mg/ml of ribonuclease A (Colbiochem, Cat. #556746) for 30 min at room
temperature, ﬁltered through 40-μm nylon mesh, and analyzed by ﬂow cytometry
for the DNA content.
Colony assays. Cells were transduced with a lentivirus expressing ATRX shRNA
#9, ATRX shRNA #20, or scrambled control shRNA at multiplicity of infection 5
for 24 h. Then the cells were harvested, suspended into single cells in a pre-warmed
medium, counted and seeded at 300 cells/well in six-well plates. The plates were
shaken gently every 1–2 min for 10 min. Fresh medium was added every 4 days.
After 2–3 weeks when colonies were visible, cells were washed, ﬁxed in 1% paraformaldehyde for 30 min at room temperature and stained with 0.1% crystal
violet.
CRISPR/Cas-9 targeting ATRX and DAXX. Guide RNAs (gRNAs) were designed
targeting an early and conserved exon between isoforms of the hATRX and hDAXX
genes. Bioinformatics analysis was performed to identify gRNAs with at least 3 bp
of mismatch to other sites in the human genome. gRNAs were further validated in
human K562 cells for cutting efﬁciency using targeted deep sequencing.
Two validated hATRX (g2 and g5) and one hDAXX (g11) gRNAs were used in
this study. The sequences of gRNAs are:
hATRX.g2: 5′-CTGCACTGCTTGTGGACAACNGG-3′
hATRX.g5: 5′-CAATGAAGGGTGTCTATAAANGG-3′
hDAXX.g11: 5′-GGTTCTTCTGACAGTAACGANGG-3′
Cells were transiently transfected with PC526-Cas-9 plasmid (to express Cas-9;
Addgene # 43945), either ZZ52.hATRX.g2 or ZZ52.hATRX.g5 (to express hATRX
gRNA; the backbone plasmid Addgene # 43860) and pUB-GFP (to express GFP;
Addgene # 11155) in a ratio of 7:7:1, respectively using Mirus 2020 (Mirus
Biotechnology Cat. # 2020). After 48 h, the cells were sorted for GFP-positive cells.
Half of the sorted cells were pelleted immediately and stored at −80 °C and the
remaining cells were seeded in six-well plates and harvested at different time
points. To test for the NHEJ efﬁciency after CRISPR targeting in IMR32 cells, we
transfected the cells with the same mix of plasmids but added a control plasmid
expressing gRNA targeting the hAAVS1 locus (Addgene # 41818) in a ratio of
4:4:6:1 for hAAVS1.gRNA: ATRX.gRNA: Cas-9: GFP expressing-plasmids,
respectively. DNA was extracted from the cell pellets using DNAeasy kit (Qiagen,
Cat. # 69504) and PCR was done to amplify the targeted region using primers to
which MiSeq adaptors were annexed and the gel-puriﬁed PCR products were
subjected to deep sequencing.
The primers used are (adaptor sequences are underlines)
hATRX F: TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGGAATTT
GCCAAGGTTGTCATGTGC
hATRX R: GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTTTCTT
CAAGACTGTGCCCTCAAAGGCC
16

hAAVS1 F: TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGTCCC
CGAGCTGGGACCA
hAAVS1 R: GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTAGGAA
GGAGGAGGCCTAAGGATGGG
The percentage of indels was determined using CRISPResso software as
described before69.
Comet assay. Alkaline comet assay was done using CometAssay Reagent Kit
(Trivegen, Cat. # 4252-40-K) following the manufacturer’s protocol. In brief, cells
were harvested and suspended in PBS buffer at a concentration of 1 × 105 cells/ml.
Cells were combined with LMAgarose in a ratio 1:10 at 37 °C and 50-μl of the mix
was spread over the CometSlide. The doxycycline-treated and untreated samples
were loaded onto two different wells on the same slide. Slides were left at 4 °C for
30 min in the dark to allow agarose to polymerize. The slides were then incubated
in a freshly made Alkaline Unwinding Solution (200 mM NaOH, 1 mM EDTA,
pH > 13) overnight at 4 °C in the dark. Electrophoresis was done at 4 °C for 30 min
at 21 volts in the Alkaline Electrophoresis Solution (200 mM NaOH, 1 mM EDTA,
pH > 13). The slides were washed twice in dH2O, dried at 37 °C and stored in the
dark. To analyze the samples, nuclei suspended in the agarose gel were stained by
100-μl of SYBR Gold (Thermo Fischer, Cat. #S 11494) diluted 1:30,000 in TE buffer
(10 mM Tris-HCL pH 7.5, 1 mM EDTA). Then the slides were rinsed in water and
dried completely at 37 °C. Slides were examined by a ﬂuorescence microscopy for
excitation/ emission: 496/522 and 10–15 images were taken per sample. Percentage
of DNA in the tail was quantiﬁed in the images using ImagJ software by measuring
ﬂuorescence intensity in the tail/total ﬂuorescence × 100. Mann–Whitney nonparametric statistical test was used to compare the scores in the samples with or
without doxycycline.
Spectral karyotyping (SKY) analysis. Cells were treated with colcemid for 5 h at
37 °C then the cells were harvested for cytogenetic analysis. SKY analysis was done
using a commercially available probe from spectral imaging (Carlsbad, CA) following the manufacturer’s protocol. Fifty metaphase cells from every sample were
scored for the presence of DNA fragmentations. Statistical analysis was done using
Fischer exact test.
Hydroxyurea sensitivity. The cells were seeded in 96-well plates at a density of
2500 cells per well over night. Next day (day 0), the medium was changed with a
fresh medium with or without 2 μg/ml doxycycline. After 24 h of doxycycline
treatment (day 1), the medium was changed again with fresh medium containing
serially diluted hydroxyurea with or without doxycycline. At day 4, the cell viability
was assessed using the CellTitre-Glo cell viability assay kit (Promega, Cat. # G7572)
using PHERAstar FSX (BMG Labtech, San Diego, California).
Inducible MYCN. To make the doxycycline-inducible cell lines, we used pLenti4/
TO/V5 DEST system (Invitrogene, Cat. # V480-20) following the manufacturer’s
protocol. In brief, cells were transduced with the pLenti4/TO lentivirus to constitutively express the Tet repressor and the cells were selected with 10-μg/ml
blasticidin-HCL (Thermo Fisher, R21001) in the medium. The cells were then
transduced with the V5 DEST-MYCN or V5 DEST-control lentivirus and were
selected with 10-μg/ml zeocin (Thermo Fisher, R25001) in the medium. The V5
DEST-MYCN virus was a gift from the Freeman lab at St. Jude Children’s Research
Hospital. The cells were maintained in a selective medium containing 5-μg/ml
blasticidin-HCL and 5-μg/ml zeocin. We also cloned MYCN into another doxinducible system using Lenti-X Tet-One (Takara Cat# 631847) following manufacturer protocol. We conﬁrmed the sequence of the construct by sanger sequencing. Cells were transduced with Lenti-X Tet-One lentiviruses containing MYCN or
with the empty vector. Selection for the cells containing the construct was done
using puromycin and the cells were maintained in puromycin-containing media.
Induction of MYCN expression was done by adding doxycycline to the medium to
a ﬁnal concentration of 1–2 μg/ml.
Growth curve. The cells were plated in six-well plates at a density of 50,000 cells
per well over night. Then the medium over the cells was changed with a fresh
medium with or without 1–2-μg/ml doxycycline. Three wells from each of the cell
lines were harvested every day and counted for the total number of cells per well
using a hemocytometer.
Live imaging. Live cell time-lapse imaging experiments for SKNMMMYCN in the
presence or absence of doxycycline were performed using a Nikon C2 confocal
conﬁgured on a TE2000E2 microscope with a 20 × 0.8 NA Plan Apo lens (Nikon
Instruments Inc., Melville, NY). A 640 nm DPSS lasers was used to simultaneously
excite Annexin V-Alexa Fluor 647 and generate the DIC images. During imaging
experiments, the cells were maintained at 37 °C and 5% CO2, and images were
collected every 30 min for 67 h. Images were acquired and processed using NIS
Elements software.
In vivo mixing experiment. SKNMMMYCN and SKNMMCONT cells were labeled
with luciferase-YFP (yellow ﬂuorescent protein) using a lentivirus. Two mixed cell
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pools were prepared in a 1:1 ratio: labeled SKNMMMYCN cells/unlabeled
SKNMMCONT and labeled SKNMMCONT /unlabeled SKNMMMYCN. Cell mixes
were injected in the para-adrenal region of the mice (four million cells/mouse) with
ultrasound guidance under anesthesia as explained before. In this experiment, we
used NOD.CB17-Prkdcscid/J female mice (Jackson laboratories, Stock # 001303).
The mice were followed up for the tumor formation using ultrasound scanning
every 2 weeks, xenogen signal every week and palpation every week. Mice were
enrolled in the study when the tumor was at least 14 mm3 in size using the
ultrasound scanning. Enrolled mice were randomly assigned to receive either
doxycycline (2 mg/ml) in the drinking water or continue on regular water.
The labeled/unlabeled cell mixes were also maintained in culture and the ratio
of YFP-expressing cells in each cell mix was determined weekly using ﬂow
cytometric analysis.
Lactate measurements. Lactic acid was measured using Lactate Assay Kit (Sigma
Cat. # MAK064) following the manufacturer’s protocol. The absorbance at 570 nm
(A570) was measured for a colorimetric detection of the lactate using the microplate reader SpectraMax-M5 (Molecular Devices, Sunnyvale, California).
GC-MS-mediated analysis of 13C-labeled TCA metabolites. The analytical
procedure applied was based on the one previously published28. In brief, cells were
cultured in glutamine-free medium (10% fetal bovine serum (FBS), penicillin/
streptomycin) supplemented with 4 mM of standard glutamine or [U-13C]-glutamine (CLM-1822-H); Cambridge Isotope Laboratories, Inc. for 5 h. Next, cells were
trypsinized, washed with ice-cold saline solution, snap-frozen, and stored in liquid
nitrogen for further processing. Extraction of hydrophilic metabolites was performed using two volumes of methanol/water solution (2:1 v/v, high-performance
liquid chromatography (HPLC)-grade, spiked with 5 nM of norvaline as internal
standard), homogenization and mixing with one volume of chloroform (HPLCgrade). Derivatization with 2% methoxylamine-HCl solution and GC-MS-grade
MTBSTFA + 1% t-BDMCS reagent was performed as previously described. Samples were analyzed in split-less mode using Agilent 7890B GC system equipped
with a 5977B MSD, Agilent VF5ms, + 1 m EZ, 60 m, 0.25, 0.25 μM column, helium
carrier gas and Mass Hunter software package. Chromatographic gradient conditions: separation time 36 min; start at 80 °C, 1 min; ramp to 250 °C at 7oC/min;
ramp to 300 °C at 50 °C/min and hold for 9 min. MSD settings: source 150 °C;
quadrupole 150 °C; interface 300 °C; injector 250 °C; EI source 70 eV, EI pressure
1.8 × 10−5 torr. Signals were acquired using SIM mode conditions as described
before (5) as well as using scanning mode (full scan range 50–500 m/z at ~ 2 scans/
s (N = 3)). Enrichment of C13-labeled isotopomers of analyzed compounds was
corrected by natural abundance using “standard glutamine” medium-incubated
sample as reference.
Detecting metabolites using CE-TOFMS. MYCN-induced and un-induced
SKNMMMYCN cells were grown on either glutamine-free or glucose free completed
medium supplemented with [U-13C]-glutamine (CLM-1822-H) or [U-13C] glucose
(CLM-1396); Cambridge Isotope Laboratories, Inc. for 18 h. Metabolites were
extracted from the cells following the protocol provided by Human Metabolome
Technology Inc, (Boston, MA). Samples were ﬁltered through 5-kDa cutoff ﬁlter
(ULTRAFREE-MC-PLHCC, Human Metabolome Technologies, Yamagata, Japan)
and sent to Human Metabolome Technologies Inc. for analysis. We also sent snapfreezed medium from the same samples for metabolomic analysis.
Metabolites were measured in both Cation and Anion modes using Agilent
Capillary electrophoresis–time of ﬂight mass spectrometry (CE-TOFMS) system
(Agilent Technologies Inc.) and Capillary: Fused silica capillary i.d. 50 μm Å ~ 80
cm with the following conditions:
Cationic metabolites (cation mode):
Run buffer: cation buffer solution (p/n: H3301-1001)
Rinse buffer: cation buffer solution (p/n: H3301-1001)
Sample injection: pressure injection 50 mbar, 10 sec
CE voltage: positive, 27 kV
MS ionization: ESI positive
MS capillary voltage: 4000 V
MS scan range: m/z 50–1000
Sheath liquid: HMT sheath liquid (p/n: H3301-1020)
Anionic metabolites (anion mode):
Run buffer: anion buffer solution (p/n: H3302-1021)
Rinse buffer: anion buffer solution (p/n: H3302-1021)
Sample injection: pressure injection 50 mbar, 25 sec
CE voltage: positive, 30 kV
MS ionization: ESI negative
MS capillary voltage: 3500 V
MS scan range: m/z 50–1000
Sheath liquid: HMT sheath liquid (p/n: H3301-1020)
Data processing and analysis
Data processing and analysis were done by Human Metabolome Technologies.
In brief, MasterHands ver. 2.17.1.11 software was used to extract peaks detected in
CE-TOFMS analysis in order to obtain m/z, migration time (MT), and peak area.
Relative peak area was calculated as:
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Relative peak area = metabolite peak area/(internal standard peak area × sample
amount)
Signal-noise ratio (S/N) = 3 was set as a threshold for peak detection limit.
Human Metabolome Technologies target library was used to identify putative
metabolites and their isotopic ions on the basis of m/z and MT with tolerance ± 0.5
min in MT.
Absolute quantiﬁcation was performed in total amount of each detected
metabolite. All the metabolite concentrations were calculated by normalizing the
peak area of each metabolite with respect to the area of the internal standard and
by using standard curves, which were obtained by single-point (100 μM)
calibrations.
pH measurements. Five milliliters of the medium were centrifuged at 500 × g for
5 min to remove suspended cells and the pH was measured using a pH meter
(Mettler Toledo, Colombus, OH).
Mitotracker green and TMRE assays. MitoTracker Green FM (Thermoﬁsher
# M7514) or Tetramethylrhodamine ethyl ester perchlorate (TMRE, Thermoﬁsher
# T669) was added directly to the medium to a ﬁnal concentration of 200 nM or
50 nM, respectively. After 20 min incubation at 37 °C, the medium was removed
and the cells were washed twice in 1 × PBS and harvested. Fluorescent intensity was
measured in at least 20,000 cells as suggested by the manufacturer. Data are presented as a geomean ±95% conﬁdence interval. The comparison between the
ﬂuorescence intensity in cells with or without doxycycline was done using the twotailed t test.
Seahorse assay. Mitochondrial function and glycolytic ﬂux were determined
using Seahorse XFe 96 extracellular ﬂux analyzer (Seahorse, Agilent) as oxygen
consumption rate and extracellular acidiﬁcation rate using “Mito-stress test” or
“Glycolysis stress test” methods, respectively. Cells harboring inducible N-Myc
overexpression vector were treated ±DOX for 2, 3, 4, or 5 days. Next, cells were
plated onto 96-well plate using several strategies to verify experimental outcome.
All plating approaches yielded consistently very similar results. In particular, cells
were plated at two different concentrations (4 × 104 or 2.5 × 104 cells/well) in
multiple wells (i) allowing to attach for 6 h or (ii) overnight to ﬁbronectin-coated
wells, or (iii) were attached readily after re-plating using Cell Tak cell adhesive
(Corning). FBS-free Seahorse XF RPMI medium (without Phenol Red, Agilent) was
supplemented with 2 mM glutamine, 1 mM sodium pyruvate and 2 g/L glucose (for
“Mito-stress test”) or with 2 mM glutamine (for “Glycolysis stress test”). Measurements were performed at basal state and following serial injections of: oligomycin (1 μM), FCCP (0.5 μM) and rotenone/antymycin A (0.5 μM/1 μM) for
“Mito-stress test” or of glucose (10 mM), oligomycin (1 μM), and 2-deoxy-glucose
(20 mM) for “Glycolysis stress test”.
TEM analysis of mitochondria. The samples were ﬁxed with 2.5% glutaraldehyde,
2% paraformaldehyde in 0.1 M sodium cacodylate buffer pH 7.4, and post ﬁxed in
2% osmium tetroxide in 0.1 M cacodylate buffer with 0.3% potassium ferrocyanide
for 1.5 h. After rinsing in the same buffer, the tissue was dehydrated through a
series of graded ethanol to propylene oxide, inﬁltrated, and embedded in epoxy
resin and polymerized at 70 °C overnight. Semithin sections (0.5 micron) were
stained with toluidine blue for light microscope examination. Ultrathin sections
(80 nm) were cut and imaged using an FEI Tecnai 200 Kv FEG Electron Microscope with an ATM XR41 Digital Camera. To score mitochondrial damage, 50
images from every sample were selected in which the nucleus and at least ﬁve
mitochondria were visible at 5 K magniﬁcation. Images of these proﬁles were taken
at 29 K with some portion of the nucleus visible, printed and all mitochondria
proﬁles were scored blindly. Mitochondria were scored 0 = normal (aligned cristi
and normal outer membrane), 1 = abnormal (swollen and disorganized cristi or
disrupted outer membrane) or 2 = very abnormal (both swollen and disorganized
cristi and severe outer membrane disruption).
Gamma H2AX immunostaining. Cells were harvested and incubated on poly-Llysin-treated (Sigma, Cat. # 8920) slides for 30 min at 37 °C. The cells were ﬁxed in
4% paraformaldehyde in PBS at 4 °C overnight, blocked by normal donkey serum
for 1 h at room temperature and incubated with mouse anti Phospho Ser139histone H2AX antibody (Millipore, Cat. # 5-636) 1:10,000 overnight at 4 °C. The
slides were then washed three times in PBS and incubated with donkey anti-mouse
Cy3 IgG antibodies (Millipore, Cat. # AP192C) 1:500 for 1 h at room temperature.
The slides were washed three times in PBS, counter-stained with DAPI for 10 min,
washed three times in PBS and mounted with Prolong Gold Antifade Mountant
(Thermo Fischer, Cat. # P36930).
Measuring ROS. ROS was assayed using 2',7'-dichloroﬂuorescin diacetate
(DCFDA) cellular ROS detection assay kit (Abcam # ab113851) or CellRox Green
(ThermoFischer # C10444) following manufacturers’ protocol. For DCFDA cellular
ROS detection assay kit, cells were plated overnight in 96-well plates (25,000 cells
per well) in their complete medium with or without doxycycline. The ﬂuorescence
excitation/emission 485/535 was measured using the microplate reader
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SpectraMax-M5 (Molecular Devices, Sunnyvale, California). For CellRox Green,
cells grow in 10-cm plates. CellRox Green was added to the medium 1:500 and
incubated for 30 min then cells were harvested and analyzed using ﬂow cytometry.
Measuring cellular glutathione. The cells were plated in 96-well plates overnight
at a density of 6000 cells per well in their complete medium with or without
doxycycline. Glutathione concentration per well was measured using GSH-Glo
Glutathione Assay Kit (Promega # V6911) according to the manufacturer’s protocol. The luminescence was measured using PHERAstar FSX (BMG Labtech, San
Diego, California).
Drug screening. Cell screening was done on MYCN-induced and un-induced
SKNMMMYCN cells as previously described54 with the following modiﬁcations: to
determine optimal cell plating density, SKNMMMYCN cells were plated on a ﬂatbottomed, white 96-well plate (Corning Cat#3917), at eight different cell densities
ranging from 0 cells/well to 10,000 cells/well; 12 wells per cell intensity per plate.
Twenty-four hours after plating, medium was changed with or without doxycycline. Medium was changed after that with or without doxycycline every 2 or
4 days. One plate from every testing condition was read every day for 11 days using
CellTiter-Glo (‘CG’, Promega Cat#G7573) on PHERAstar FSX (BMG Labtech, San
Diego, California). Cell density of 1250 cells per well and medium change once
every 4 days was determined to have good signal to noise separation while
maintaining logarithmic growth in both induced and un-induced cells. We tested
different dimethyl sulfoxide (DMSO) concentrations for the selected cell density
and conﬁrmed minimal cell death with up to 0.197% DMSO. Positive control
compound selection was performed with eight positive control compound candidates (doxorubicin HLC, staurosporine, etoposide, SN-38, bortezomib, cyclohexamide, panobinostat, and TAKA123) arrayed in single-point concentration and 1:3
dilution series. Based on successful cell killing Staurosporine was chosen as positive
control for cell screenings. Assay validation in 384-well plates was performed with
staurosporine.
Dose–response curve experiment. A schematic representation of the
dose–response curve experiment is illustrated (Supplementary Data 14). Cells were
plated in 96-well plates (Corning Cat#3917) at 1250 cells/100 μL; 12 cell plates per
compound plate. Approximately 24 h following plating, medium was changed with
fresh medium with or without doxycycline; six-cell plates per a compound plate
each. Two days after MYCN induction, medium was changed again with fresh
medium with or without doxycycline and cells were drugged with the compound
plates and a positive control plates using a Biomek FX (Beckman Coulter) liquid
handler equipped with a pin tool. The pin tool transferred 112 nL compound stock,
resulting in 890-fold compound dilution. After 3 days of drugging, half of the plates
were read. On day 4 post drugging, medium was changed with fresh medium again
with or without doxycycline and fresh drugs were added to the medium using the
Biomek FX. After 4 days of the second drugging, the other half of the plates were
read. The compound plate contained compounds dissolved in DMSO arrayed in a
1:3-fold dilution series in columns 1–10 with eight compounds per plate (target
concentration 10 mM or 1 mM). The positive control plate was empty from columns 1–10; in columns 11–12, it contained DMSO and the positive control. Two
biological replicates were performed for each 8 days experiment, with three technical replicates per biological replicate.
Drug screening analysis. Normalization, ﬁtting, and visualization of
dose–response experiments were performed using custom code written in the R
programing language (version 3.3.2, R Core Team (2016). R: A language and
environment for statistical computing. R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org/.).
Dose–response curve data analysis for cytotoxic compounds was done as
previously described before54. Raw CellTiter-Glo (CTG) luminescence signals
(RLU) were ﬁrst log2 transformed, then normalized to the mean of the positive and
negative controls on each plate.
In order to detect drugs that reduced MYCN-induced cell death, traditional
dose–response analysis was not appropriate because protective drugs would often
protect at low concentrations, but eventually induce cytotoxicity at high
concentration. To detect a protective effect, we needed to quantify the increase in
CTG signal at low concentration before any decrease in signal at high
concentration. To do so, the CTG RLUs from all wells were ﬁrst log2 transformed
for each plate, the value for each well was then normalized by subtracting out the
mean log2 RLU for negative control wells. The normalized activity of each
compound was then ﬁt as a function of the log10 drug concentration using a
smooth spline (smooth.spline function in R with default parameters). For each ﬁt,
the area under the curve (AUC) for the portion of the spline with RLU above the
RLU of the lowest drug concentration tested was calculated. Higher values for this
AUC metric indicate greater protection against loss of cell viability as measured by
the CTG assay.
CUX2 expression in SKNMMMYCN cells. SKNMMMYCN cells were transduced by
a lentiviral vector (pLenti-C-mGFP-P2A-Puro) from Origene expressing either
CUX2 (Cat# RC222063L4V) or GFP control construct (Cat# PS100093V). GFP18

positive cells were sorted after 48 h and maintained in a selective media containing
1.5-μg puromycin per ml.
Statistics and reproducibility. We have made every effort to ensure reproducibility of our data by, when possible, repeating the experiments using independent
samples, including positive and negative controls and using multiple approaches to
conﬁrm our observations. We stated the sample number for each experiment and
how many times each experiment was repeated in the ﬁgure legends. However, the
following experiments were done once:
Fig. 1f–i: This was a unique case in which there was a discrepancy between
COG FISH report and next-generation sequencing report. This sample was
carefully studied as described in the results section.
Fig. 3b: This is the ﬁrst and only O-PDX developed from ATRX-mutant
neuroblastoma, as explained in the text.
Fig. 5h: This experiment was done to conﬁrm the high-throughput screening
and was done in a dose response.
Fig. 5i: This experiment was done once. However, the ability of RA to reduce
MYCN level is well-established in literature70.
Supplementary Fig. 1B–S1E: Was done to all the clinical samples as mentioned
in the material and methods.
Supplementary Fig. 4H. This experiment was done once. However, this
experiment is another evidence for the increase in replicative stress when ATRX is
inactivated and MYCN is ectopically expressed in different cells as shown in Fig. 5.
Supplementary Fig. 7C: This experiment was done once as another readout for
increase ROS shown in Supplementary Fig. 7D.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

Data availability
Whole-genome bisuﬁte sequencing data and ChIP-seq data have been deposited in the
EMBL-EBI database under the accession code EGAS00001003257. Whole-exome
sequencing data have been deposited in the EMBL-EBI database under the accession
code EGAS00001002528. All of our extensive epigenetic data and analysis are freely
available in a cloud-based viewer (https://pecan.stjude.cloud/proteinpaint/study/
mycn_nbl_2018). All O-PDX tumors described here are freely available with no
obligation to collaborate through the Childhood Solid Tumor Network (http://www.
stjude.org/CSTN/). We downloaded G4 Motifs from supplementary data of Du et al.
200959. We downloaded 169,222 R-Loop domains in genic and proximal regions from
(http://rloop.bii.a-star.edu.sg/). All the other data supporting the ﬁndings of this study
are available within the article and its Supplementary Information ﬁles and from the
corresponding author upon reasonable request.
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